

# Univ.-Prof. DDr. Gregor K. Wenning

Universitätsklinik für Neurologie  
Medizinische Universität Innsbruck  
Abteilung für Neurobiologie  
Anichstrasse 35, A-6020 Innsbruck  
T: +43 512 504-23933  
M: +43 512 504-81811  
F: +43 512 504-23912  
Email: gregor.wenning@i-med.ac.at

Home Address:  
Krippstrasse 21, 6067 Absam i.T.,  
Austria  
T: +43 5223 204805  
M: +43 676 5964772

## CURRICULUM VITAE

Name: Gregor Karl WENNING  
DOB: 21. March 1964 in Horstmar GERMANY  
Parents: Karl-Heinz and Elisabeth Wenning  
Married to: Prof. Roberta Granata, 2 sons  
(Maximilian 15 and Marco 13)



Important Publications:	<ul style="list-style-type: none"><li>• Wenning et al. Brain 1994;117-835-845</li><li>• Wenning et al. Ann Neurol 1997,42:95-107</li><li>• Gilman et al. Clin Aut Res 1998, 8:359-362</li><li>• Wenning et al. Mov Disord 2004;19(12):1391-1402</li><li>• Wenning et al. Ann Neurol 2008, 64:239-46</li></ul>
Positions	Head, Division of Neurobiology Principal Investigator, Parkinson and Movement Disorder Centre Executive Board, Department of Neurology and Neurosurgery Coordinator, European MSA Study Group ( <a href="http://www.emsa-sg.org">www.emsa-sg.org</a> )
Awards	<ul style="list-style-type: none"><li>• German National Scholarship Foundation, 1983-1990</li><li>• UK PD Society, 1992-1994</li><li>• Austrian PD Society Award, 1998 (First recipient)</li><li>• Oppenheimer Prize, 2004 (First recipient)</li></ul>
Areas of Research	<ul style="list-style-type: none"><li>• Multiple system atrophy and related atypical parkinsonian disorders</li><li>• Autonomic function testing</li><li>• Advanced MRI in neurodegenerative disorders</li><li>• Therapeutic interventions in MSA (animal modeling, drug screening, phase 2/3 trials)</li></ul>

1. School	
1970-1983	Primary School (St. Gertrudis, Horstmar/Westfalia) and Grammar School (Gymnasium Arnoldinum, Burgsteinfurt/Westfalia)
08.06.1983	A-Level (Average Mark 1,2)

<b>2. University</b>	
1983-1990	Medical Student at Westfalian Wilhelm University, Münster/Westfalia/GER (preclinical ("Physikum" ) and clinical exam („ärztliche Prüfung“) each with total mark 2)
1983-1990	Fellow of the German National Scholarship Foundation
1989-1990	Final year at University Hospital Münster (Internal Medicine and Surgery) and at National Hospital for Nervous Diseases, Queen Square, London (Neurology, Prof. I. McDonald)
01.01.1991	Residency, Department of Neurology, University Hospital, Tübingen GER (Head Prof. Dr. J. Dichgans)
17.12.1991	Doctorate („summa cum laude“) at Westfalian Wilhelm University, Münster/Westfalia GER (Topic: Investigations of long ascending and descending pathways in motor system degenerations (supervisor: Prof.Dr. A. Ludolph)
10.07.1992	Practitioner Status, Physicians`Council, Münster, Westfalia GER
06.03.1995	Resident, Department of Neurology, University Hospital, Innsbruck (Prof. W. Poewe)
01/1996	PhD, University of London (Multiple system atrophy)
since1997	Foundation of an experimental laboratory for neurodegeneration research at the University Department of Neurology, Innsbruck (major areas of interest: characterization of MSA rat and mouse models; neurotransplantation and neuroprotection in MSA rat and mouse models; alpha-synuclein in MSA pathogenesis; translational research towards interventional therapies in MSA; in vivo pinhole SPECT/MRI of dopaminergic projections in PD/HD rat models)
1997/98	Residency at the University Department of Psychiatry, Innsbruck (Head: Prof. Dr. H. Hinterhuber)
1998/99	Residency at the University Department of Internal Medicine, Innsbruck (Head: Prof. Dr. J. Patsch)
01/1999	Founding Coordinator of the European MSA Study Group (EMSA-SG; <a href="http://www.emsa-sg.org">www.emsa-sg.org</a> ) with 24 European partner sites (Objective: Registry, Scale Development, Natural History Study, Genetics, Experimental Studies, Intervention trials such as Growth Hormone (SERONO, Phase II), Minocycline MEMSA (Phase II) and Rasagiline (TEVA, Phase IIb); 5FP EC Support)
01.07.1999	Habilitation at the Medical Faculty of Innsbruck University (Topic: MSA: clinical and experimental findings)
24.08.1999	Associate Professor of Neurology, Medical Faculty, University of Innsbruck
31.08.1999	Board certified Neurologist and Psychiatrist (Austrian Chamber of Physicians)
since 09/1999	Coordination of Research Program of the Federal Ministry of Science (Progression of striatonigral Degeneration in MSA) (Objective: Natural history of MSA-P as determined by rating scales and neuroimaging indices incl. diffusion-weighted imaging, MR volumetry, and SPM based analysis of $\beta$ -CIT/IBZM SPECT; further progression markers in MSA animal models)
Since 1999	Consultant Neurologist with the following assignments in general neurology: intensive care unit, emergency room, ward rounds, outpatient service.

	PI at the Parkinson and Movement Disorder Centre including MSA drug trials at the clinical trial centre and DBS service (ca. 120 patients with PD, dystonia, ET, tardive dyskinesias)
2001	EEG Diploma and Member, Austrian Society for Clinical Neurophysiology Austrian Clinical Trial Diploma
10/2002	Rejection of a Full Professorship at the Department of Neurology, Ulm, GER
Since 2004	Foundation of the Autonomic Function Unit at the University Department of Neurology, Innsbruck (Syncope work-up, diagnosis and management of NOH, MSA trials)
05/2006	Full Professor of Clinical Neurobiology at the Medical University Innsbruck
Since 2007	Establishment of a Neuroscience PhD Excellence Programme "Signal Processing in Neurons" at the Medical University Innsbruck (total funding 3,2 Mill Euro for 6 years)
12/2007	MSC (Master of Health Economics), Private university for health science, medical information technology and engineering (UMIT), Hall i.T., Austria
2011	Deputy Speaker, SFB Research Program „Calcium signaling in chronic CNS diseases“ (total funding 5 Mill Euro for 8 years)

3. Memberships in scientific associations	
AAN	American Academy of Neurology Section on Autonomic Nervous System Section on Movement Disorders Section on History
AAS	Austrian Autonomic Society
ABN	Association of British Neurologists
AG-ANS	Arbeitsgemeinschaft Autonomes Nervensystem
ANA	Austrian Neuroscience Association
BSS	Brain Stem Society
DGN	Deutsche Gesellschaft für Neurologie
DPG	Deutsche Parkinson Gesellschaft
EFAS	European Federation of Autonomic Societies
EHDN	European Huntington's Disease Network
EMSA-SG	European MSA Study Group
MDS	Movement Disorder Society Task Force on Diagnostic Criteria for PD and related disorders Force on Rating Scales in Parkinson's disease UPDRS Revision Taskforce
MDS-ES	Movement Disorder Society European Section
NECTAR	Network for European Intracerebral Transplantation and Restoration
NEST-HD	Network for Striatal Transplantation in Huntington's Disease
ÖAG	Österreichische Alzheimer Gesellschaft
ÖGN	Österreichische Gesellschaft für Neurologie
ÖPG	Österreichische Parkinson Gesellschaft
SFN	Society for Neuroscience

<b>4. Fellowships and stays abroad</b>	
<b>Fellowships</b>	
1983-1990	German National Scholarship Foundation
1992-1994	UK PD Society Fellow (Topic: clinicopathological studies of MSA, Institute of Neurology, London (Professor Marsden, Professor Quinn) (grant: € 119.550,--))
<b>Stays abroad</b>	
1986-1987	"First clinical year" at King's College School of Medicine, London, England
1990	Final clinical year at National Hospital for Nervous Diseases, Queen Square, London (Prof. I. McDonald, Prof. C.D. Marsden)
01.01.1992 - 31.12.1994	Clinical Research Fellow, Honorary Clinical Assistant and PhD Student, Department of Clinical Neurology, Movement Disorders Group, Institute of Neurology, Queen Square, London (Prof. C.D. Marsden, Dr. N. Quinn)
01.01.1993 - 30.06.1994	Research Fellow at Department of Pharmacology, King's College London (Prof. P. Jenner)
01.11.1993 - 30.06.1994	Honorary Clinical Assistant (Professor I. McDonald) at Moorfields Eye Hospital, London, England
01.12.1994 - 31.12.1994	Honorary Registrar (Dr Quinn) at the Department of Clinical Neurology, Institute of Neurology, Queen Square, London, England
06/1996	Research Fellow, Neuroepidemiology Branch, National Institutes of Health, Bethesda, Washington, USA (Dr I Litvan)
04-06/2000	Visiting Professor, Autonomic Function Unit, National Hospital for Neurology and Neurosurgery, Queen Square, London, England (Prof. Dr. C. Mathias)
07/2004	Visiting Scholar, Brain Repair Group, School of Biosciences, Cardiff University, Wales (Prof. S. Dunnett)
04/2005	Visiting Scholar, Wallenberg Neuroscience Centre, Section of Restorative Neurology, Lund (Prof. A. Björklund)
07/2008	Visiting Professorship, Western General Hospital, Toronto (Prof. A. E. Lang)

<b>5. Board Activities</b>	
since 1999	EMSA-SG Board (Coordinator)
2001-2002	International Executive Committee of the Movement Disorder Society – European Section (MDS-ES)
2001-2004	Head, MDS Membership Committee
since 2002	Member, Editorial Board Journal of Neural Transmission
since 2002	Head, Austrian Autonomic Society
2002-2004	Member, Editorial Board Movement Disorders Journal
2003-2010	Treasurer, Austrian Parkinson Society
2005-2007	Member, MDS Bylaws Committee
Since 2005	Board Member NECTAR (=Network for European Intracerebral Transplantation and Restoration)
2009-2011	Secretary, MDS-ES
since 2006	Member, Editorial Board Synapse

Since 2007	Member, Task Force on Rating Scales in Parkinson's disease, Movement Disorders Society
Since 2008	Member, Brain Stem Society
Since 2009	Member, Editorial board Neurobiology of Disease
Since 2010	Member, European Huntington's Disease Network (EHDN)
Since 2010	Austrian Representative for Guidelines on Chorea and Syncope of the German Neurology Society

<b>6. Invited international Talks</b>		
1	12.03.1993	Institute of Neurology, London. The natural history of multiple system atrophy.
2	05.04.1993	Hospital General de Santo Antonio, Oporto. The natural history of multiple system atrophy.
3	27.08.1993	Parkinson's Disease Society Brain Bank, London. Clinicopathological correlations in multiple system atrophy.
4	22.11.1993	Parkinson's Disease Society Brain Bank, London. The cerebellar pathology of multiple system atrophy.
5	29.03.1994	11 <sup>th</sup> International Symposium on Parkinson's disease, Rome. Multiple system atrophy
6	28.04.1994	Institute of Neurology, London. Olivopontocerebellar pathology in multiple system atrophy.
7	11.05.1994	UK Parkinson's Disease Society, London. Parkinsonism plus syndromes.
8	18.05.1994	Institute of Neurology, London. Advanced Short course in movement disorders: multiple system atrophy.
9	25.05.1994	Istituto di Neurologia. Universita Cattolica del Sacro Cuore, Policlinico Gemelli, Rome. Survival studies in multiple system atrophy.
10	21.06.1994	Universitätsklinikum Rudolf-Virchow, Freie Universität Berlin. Klinische und experimentelle Studien zur Multisystematrophie.
11	20.09.1994	Institute of Neurology, London. Short course for Norwegian neurologists: Multiple system atrophy - what is it?
12	20.10.1994	Institute of Neurology, London. Experimental studies of neural transplantation in a rat model of striatonigral degeneration.
13	15.05.1996	Wissenschaftliches Kolloquium, Universitätsklinik für Neurologie Tübingen. Multisystematrophie - ein atypisches Parkinson-Syndrom. Multiple system atrophy – an atypical
14	28.08.1996	Colloquium Neurologie, Hamburg. Atypische Parkinson-Syndrome.
15	03.09.1996	Asian Oceanina Congress of Neurology, Seoul. The pathology of multiple system atrophy.
16	08.06.1997	Basal Ganglia Club Meeting of the Austrian, Italian and Slovenian Basal Ganglia Clubs, Tarvisio. Current status of fetal mesencephalic transplantation in Parkinson's disease
17	02.07.1998	III International Congress of Pathophysiology, Lahti. Natural history of Parkinson's disease – assessment, methods and therapeutic interventions.
18	05.03.1999	1. Kongreß der Deutschen Parkinson-Gesellschaft e.V., Würzburg. Multisystematrophie.

19	05.05.1999	Kolloquien der Neurologischen Klinik der Medizinischen Hochschule Hannover. Aktuelle Aspekte zu Klinik und Therapie der MSA.
20	15.05.1999	Basal Ganglien Club Italien, Rom. Symptomatic therapy in early Parkinson`s disease.
21	02.06.1999	Basal Ganglien Club Schweiz, Bern. Molekulare Neurobiologie der Multisystematrophie.
22	18.06.1999	Neurologisches Fachkrankenhaus für Bewegungsstörungen/ Parkinson, Berlin/Beelitz. Differentialdiagnose des Parkinsonsyndroms.
23	01.- 03.09.1999	International workshop on PSP/CBD and MSA, Stowe, UK. Clinical aspects of MSA.
24	21.10.1999	Parkinson-Symposium, Neurologische Universitätsklinik, Kantonsspital Basel. Multisystematrophie.
25	23.10.1999	Parkinson-Symposium, Neurologische Universitätsklinik Mannheim. Ergebnisse klinischer Studien mit Entacapone.
26	05.11.1999	Parkinson-Symposium, Jahrestagung der Griechischen Neurologischen Gesellschaft, Athen. The clinical experience with entacapone: results from clinical trials.
27	23.10.1999	Parkinson-Symposium, Neurologische Universitätsklinik Frankfurt. Differentialdiagnose der Parkinsonsyndrome.
28	15.06.2000	6 <sup>th</sup> International Congress of Parkinson`s Disease and Movement Disorders, Barcelona. Multiple system atrophy.
29	01.07.2000	2. Baden Württembergisches Symposium über neurologische Bewegungsstörungen, Rottweil-Rottenmünster. Parkinson bei Multisystemerkrankungen.
30	13.09.2000	Alpine Basal Ganglia Club, Ljubljana. Diagnosis of atypical parkinsonism.
31	28.09.2000	Jahrestagung der Deutschen Gesellschaft für Neurologie, Baden Baden. Morbus Parkinson- Neuroprotektion: Utopie oder Wirklichkeit?
32	15.10.2000	Jahrestagung der EFNS, Copenhagen. Multiple system atrophy.
33	25.10.2000	Kolloquien der Universitätsklinik für Neurologie, Heidelberg. Multisystematrophie
34	28.11.2000	Kolloquien der Universitätsklinik für Neurologie, Dresden. Multisystematrophie.
35	10.01.2001	Kolloquien der Universitätsklinik für Neurologie, Freiburg. Multisystematrophie.
36	05.02.2001	Kolloquien der Universitätsklinik für Neurologie, Charite, Humboldt Universität, Berlin. Aktuelle Aspekte zur Diagnostik und Therapie der Multisystematrophie.
37	19.02.2001	Universitätsklinik für Neurologie, Hospital Clinic I Provincial, Barcelona. Experimental models of MSA.
38	10.03.2001	2. Deutscher Parkinson Kongreß, Bochum. Organisation des Fortbildungsseminares „MSA, PSP und andere atypische bzw. sekundäre Parkinson-Syndrome COMPACT“ mit aktiver Vortragsteilnahme (Multisystematrophie).
39	19.05.2001	Parkinsoninformationstag im Bezirksklinikum Gabersee, Wasserburg a.I. Ist alles, was zittert und steif ist, auch Morbus Parkinson?
40	26.05.2001	University Brain Bank, Barcelona. Diagnostic accuracy in Lewy body dementia.
41	07.06.2001	XVI Helsinki University Congress of Drug Research, Helsinki. Current and future perspectives of dopamine receptor agonists in the treatment of

		Parkinson's disease.
42	14.06.2001	2. Ärztesymposium Parkinson, Zihlschacht. Diagnostik und Therapie der Multisystematrophie.
43	16.06.2001	II. Parkinson-Symposium, Rügen. Differentialdiagnose des Parkinson-Syndroms.
44	27.07.- 01.08.2001	XIV International Congress on Parkinson's Disease, Helsinki. Routine cardiovascular autonomic function testing differentiates multiple system atrophy from Parkinson's disease.
45	12.09.2001	10 <sup>th</sup> Congress of the International Psychogeriatric Association, Nizza. The clinical diagnosis of dementia with Lewy bodies.
46	27.09.2001	Internationales Parkinson-Symposium, Mailand. The parkinsonisms.
47	07.12.2001	8emes Journees Therapeutique et Neurologie, Paris. Multiple system atrophy.
48	05.- 08.03.2002	3. Dt. Parkinson Kongress, Dresden. Differentialdiagnose (Fortbildungsseminar 2).
49	13.- 16.06.2002	Internationales Kolloquium, Parkinson aktuell, Chateau de Taulane
50	06.07.2002	Parkinson-Symposium, Erlangen
51	25.- 29.09.2002	75. Kongress der Dt. Gesellschaft für Neurologie, Mannheim. Halbtageskurs Neurodegeneration, Kortikobasale Degeneration.
52	24.10.2002	Satellite Symposium LIMPE' Board, Lecce. Efficacy and safety of entacapone in PD patients with suboptimal levodopa response: a six month randomised placebo-controlled double-blind study in Germany and Austria (CELOMEN).
53	27.10.2002	NNIPPS-Investigator Meeting, Reisenburg. MSA – clinical features.
54	09.- 14.11.2002	7 <sup>th</sup> International Meeting The Movement Disorder Society, Miami. Wine&Cheese Seminar Parkinsonism: PSP, MSA, CBD: Clinical update, EMSA-SG.
55	20.- 22.11.2002	International Psychogeriatric Association (IPA) Expert Conference, Budapest. Motor symptoms.
56	06.12.2002	Pharmacia-Symposium, Kopenhagen. The role of imaging in the differentiation between Parkinson's disease and Parkinson plus diseases.
57	07.12.2002	IWOP – Interaktive Fortbildung, Garmisch-Partenkirchen
58	05.- 08.03.2003	3. Dt. Parkinson-Kongress, Dresden. Organisation Fortbildungsseminar 2 „Differentialdiagnose“
59	25.03.2003	EuMeCom Fortbildung, Ziegelsee. Diagnose und Differentialdiagnose des M. Parkinson.
60	10.05.2003	Neurologie-Update, Prof. Zierz, Halle/Saale. Parkinson-Update-Charakter.
61	17.05.2003	3 <sup>rd</sup> German-Scandinavian meeting on Movement Disorders, Gothenburg-Kiel. Imaging in Movement Disorders/The role of MRT for the differential diagnostics.
62	23.05.2003	5 <sup>th</sup> Meeting of the European Federation of Autonomic Societies (EFAS), Toulouse. Neuropathology of parkinsonian syndrome perhaps focusing on MSA.
63	24.06.2003	Neuro-Kolloquium, KH München-Bogenhausen. Multisystematrophie: ein atypisches Parkinson-Syndrom?
64	06.09.2003	DGN Kongress, Hamburg. MSA und PSP.
65	13.09.2003	35 <sup>th</sup> Danube Neurological Symposium, Belgrade. Mini-symposium: What

		is new in movement disorders?, MSA – red flags: an update.
66	17.10.2003	14 <sup>th</sup> Conference of the South-East European Society for Neurology and Psychiatry, Thessaloniki. Cognitive function in Parkinson's disease.
67	18.10.2003	Universität Bochum. Psychiatrische Komplikationen bei Parkinson-Patienten.
68	05.12.2003	Annual Meeting Danish Movement Disorder Society (DANMODIS), Kopenhagen. Multiple system atrophy: clinical features, evaluation and treatment.
69	10.03.2004	Ludwig Maximilians Universität München. Clinicopathological features and pathogenesis of MSA.
70	26.04.2004	Universitätsklinik für Neurologie, Ulm. Zentrales Autonomes Versagen und Neurodegeneration.
71	29.04.2004	Klinikum Großhadern, München. Parkinson-Demenz und Demenz mit Lewy-Körperchen: zwei Namen, eine Erkrankung?
72	16.06.2004	8 <sup>th</sup> International Meeting of The Movement Disorder Society, Palazzo dei Congressi, Rome. Seminar S304 Parkinsonism – MSA: clinical update.
73	27.06.2004	ENS 2004, Barcelona. ENS course on Parkinson's Disease. The role of imaging in the differential diagnosis of parkinsonian syndromes.
74	12.07.2004	University of Cardiff. Neurotransplantation in MSA.
75	04.- 07.09.2004	8 <sup>th</sup> Congress of the EFNS, Paris. The therapeutic options for atypical parkinsonian syndromes.
76	05.10.2004	Universität Leipzig. MSA-Tiermodell.
77	06.- 09.10.2004	Jahrestagung DGN, Düsseldorf. Klinische Differentialdiagnose / Typische und atypische Parkinson-Syndrome.
78	03.11.2004	EuMeCom Fortbildung, Hannover. Parkinson – Aspekt der Diagnostik.
79	06.11.2004	Universität Erlangen. Morbus Parkinson und Stereotaxie.
80	27.11.2004	Universität Ulm. Die Rolle der MRT in der Differentialdiagnose von Parkinson-Syndromen.
81	08.03.2005	9th International MDS Congress, New Orleans. Ätiologie und Pathogenese der MSA.
82	15.04.2005	Wallenberg Zentrum, Universität Lund. Tiermodelle der MSA.
83	19.05.2005	7th EFAS Meeting, Bled. Dysautonomia progression in MSA.
84	06.06.2005	16 <sup>th</sup> ICPD, Berlin. MSA-P.
85	19.06.2005	ENS Meeting, Wien. Dysautonomia in Parkinson's syndromes: diagnosis and management.
86	03.07.2005	Parkinson Symposium, La Sapienza, Rom. Clinical neurobiology of alpha-synucleinopathies.
87	01.10.2005	Update Neurologie 2005, Düsseldorf. Therapie des Morbus Parkinson unter besonderer Berücksichtigung des höheren Lebensalters.
88	14.10.2005	Alpine Basal Ganglia Club, Graz. Update in atypical parkinson syndromes.
89	22.10.2005	Milano Parkinson 2005, Mailand. Synucleinopathies: the clinical and biological spectrum.
90	05.11.2005	Specialists Registrar Training Day, Naas. Response fluctuations in PD – clinical signs, mechanisms and treatment.
91	19.11.2005	14 <sup>th</sup> Symposium on the treatment of Parkinson's disease, Tokio. The Diagnosis of MSA.
92	21.11.2005	Koichi Medical University. MSA – State of the Art.
93	29.11.2005	dPV Regional-Treffen, Steinfurt. Erkennung und Behandlung der atypischen Parkinsonsyndrome.



94	04.02.2006	Parkinson Experten Meeting, München. Diagnostik der Parkinsonsyndrome.
95	03.03.2006	15. Frankfurter Parkinson Symposium, Frankfurt. Inwieweit spiegeln Tiermodelle (transgene und/oder toxische) die menschlichen Erkrankungen Parkinson-Krankheit, progressive supranukleäre Blickparese und Multisystematrophie wider?
96	25.05.2006	8 <sup>th</sup> EFAS Meeting, Lissabon. The role of MRI in the diagnosis of multiple system atrophy.
97	22.09.2006	79 <sup>th</sup> annual Meeting of the German Society of Neurology, Mannheim. Differential diagnosis and therapy in atypical parkinson syndromes (MSA, PSP).
98	23.09.2006	79 <sup>th</sup> annual Meeting of the German Society of Neurology, Mannheim. Video seminar on movement disorders „MSA and other atypical parkinson syndromes“
99	30.10.2006	10 <sup>th</sup> Internatinal Congress of Parkinson's Disease and Movement Disorders, Kyoto. Staging of MSA.
100	02.12.2006	Nectar Meeting, Freiburg. News on MSA.
101	03.03.2007	Augsburger Neurologie Symposium, Augsburg. Update on Clinic and Diagnostic of atypical Parkinson Syndromes.
102	09.03.2007	5 <sup>th</sup> German Parkinson Meeting, Ulm. The role of DWI and VBM in atypical Parkinson Syndromes.
103	21.- 25.3.2007	51 <sup>th</sup> Annual Meeting German Society for Clinical Neurophysiology, München. Neurophysiological Diagnostics for Differential Diagnosis of Parkinson Syndromes: What is useful?
104	27.06.2007	The PSP Internatinal Medical Workshop, Northamptonshire. A Critical Review of Symptomatic Drug Therapies for PSP including Amantadine.
105	06.07.2007	Festschrift Meeting, London. Modelling MSA.
106	25.08.2007	11 <sup>th</sup> Congress of the European Federation of Neurological Societies, Brussels. Update of PSP and MSA.
107	12.09.2007	80 <sup>th</sup> Meeting of the German Society of Neurology, Berlin. The Natural History of MSA – The EMSA Study.
108	08.12.2007	Nectar Meeting, Lund. Cell therapy for MSA. Cell Therapy in MSA: from Bench to Bedside.
109	08.03.2008	16. Parkinson-Symposium, Marburg. Neues über MSA.
110	28- 29.03.2008	EMSA-SG Annual Meeting, Neapel. EMSA Registry – Full Analysis Results. UMSARS Tape Validation.
111	24.06.2008	12 <sup>th</sup> Internatinal Congress of Parkinson's Disease and Movement Disorders, Chicago. Atypical Parkinsonism.
112	25.08.2008	12 <sup>th</sup> Congress of the European Federation of Neurological Societies, Madrid. Second Consensus Statement on the Diagnosis of MSA.
113	28.06.2008	3. Münchner Workshop Mb. Parkinson, München. Optimierte Impulskontrolle mittels kontinuierlicher dopaminerger Stimulation bei Mb. Parkinson.
114	11.09.2008	10 <sup>th</sup> International Conference on Neural Transplantation and Repair, Freiburg. Towards neurotransplantation in MSA: preclinical evidence.
115	13.09.2008	81. Kongress der Deutschen Gesellschaft für Neurologie, Hamburg. Translational research in multiple system atrophy: from bench to bedside. Second consensus statement on the diagnosis of multiple system atrophy.
116	17.09.2008	Fortbildung Kolloquium Neurologie – Atypische Parkinsonsyndrome, Jena.

		Multisystematrophien.
117	17.10.2008	6 <sup>th</sup> International Congress on Mental Dysfunction & other Non-motor Featurs in PD and related Disorders, Dresden. Neuropsychiatric changes in MSA.
118	25.10.2008	3. Kölner Parkinson-Symposium, Köln. Sind Multisystematrophien in vivo diagnostizierbar? Ist eine Behandlung möglich?
119	19.02.2009	International Workshop on Multiple System Atrophy, Tokyo. Natural History of MSA-P. European MSA Study Group.
120	27.02.2009	9. Forum Aktuelle Neurologie und Neurogeriatrie, Recklinghausen. Neues zur Therapie von Mb. Parkinson und Systematrophien.
121	07.03.2009	6. Deutscher Parkinson Kongress, Marburg. Synukleinopathien: DLB, PAF und MSA.
122	13.03.2009	Bologna Parkinson 2009, Bologna. Multiple system atrophy: from bench to bedside.
123	19.- 22.05.2009	50 <sup>th</sup> Annual Meeting of the Japanese Society of Neurology, Sendai. Recent insight into pathophysiology or pathogenesis of MSA. Up-to-date skills and key points in differential diagnosis of MSA. Perspectives of treatment for MSA. Prospect in the research on MSA: for proper diagnosis and treatment.
124	27.- 29.05.2009	1 <sup>st</sup> International Forum of Neurological diseases and Rehabilitation: MSA, Brasil. Clinical diagnosis of MSA.
125	08.- 10.06.2009	13 <sup>th</sup> International Congress of Parkinson's Disease and Movement Disorders, Paris. Advances in the etiopathogenesis of MSA: Oligodendrocytes, genes and environment. What's new in MSA?
126	07.07.2009	The PSP Association International Medical Workshop, London. Amantadine in PSP: From symptomatic to disease modifying treatment.
127	22.07.2009	Fortbildungsprogramm der Neurologischen Klinik, Erlangen. Differentialdiagnose in der Frühphase des Parkinson-Syndroms.
128	21.10.2009	Neuro-Kolloquium, Neurozentrum Feiburg i. Br.. Neues zu atypischen Parkinson-Syndromen.
130	06.03.2010	17. Parkinson Symposium Marburg. Update MSA (Genetik, Subtypen, Diagnostik, Therapiestudien).
131	30.03.2010	Medizinische Hochschule Hannover. Video-Club Bewegungsstörungen.
132	14.05.2010	12 <sup>th</sup> Congress of the European Federation of Autonomic Society, Taormina. MSA etiopathogenesis: lessons from genomic studies and transgenic models.
133	23.06.2010	Fachfortbildung Städtisches Klinikum München. Neues zu atypischen Parkinson-Syndromen.
134	23.- 28.09.2010	14 <sup>th</sup> EFNS Congress, Genf. What non-motor symptoms may be precursors of Parkinson's Disease?
135	08.10.2010	Journées Internationales de la SNF, Paris. New diagnosis criteria for multiple system atrophy and supranuclear palsy.
136	16.10.2010	5. Münchner Workshop Morbus Parkinson, München. Diagnostik und Therapie autonomer Störungen bei der Parkinson Krankheit.
137	19.11.2010	Biberach. Disease modification in MSA: relevance for Parkinson's disease
138	26.11.2010	20 <sup>th</sup> Annual Meeting of NECTAR, Freiburg. Multiple system atrophy: Current status in experimental and clinical studies.
139	10.12.2010	International Neurological-Pathological Symposium on Neurodegenerative Diseases, Olomouc. Multiples system atrophy.

140	12.03.2011	AD/PD 2011, Barcelona. Genetic and neuropathological role of alpha-Synuclein in PD and related disorders.
141	18.03.2011	ScanModis Meeting, Stockholm. MSA: Overview and update.
144	16.05.2011	I Seminari di Neurologia della Sapienza, Rom. How to diagnose Atypical Parkinsonism – a bedside approach.
145	23.05.2011	EU Rare Diseases Proposal Meeting, Frankfurt
146	07.06.2011	15 <sup>th</sup> International Congress of Parkinson's Disease and Movement Disorders, Toronto. Current management of MSA, PSP and FTDP and future targets of therapeutic intervention.
147	17.06.2011	EFAS Summer School, Lissabon. ANS and movement disorders: Diagnosis and follow-up.
148	01.07.2011	4 <sup>th</sup> MDS European Summer School for Young Neurologists, Neapel. MSA, PCP, CBD.
149	13.09.2011	15 <sup>th</sup> Congress of the European Federation of Neurological Societies, EFNS, Budapest. Update on multiple system atrophy.
150	30.09.2011	Jahrestagung der DGN, Wiesbaden. Zentral autonome Regulationsstörungen – Schlüssel zu Verständnis und Differenzialdiagnose häufiger neurologischer Krankheiten.
151	07.10.2011	Symposium on Movement disorders, Leuven, An update on MSA
152	14.10.2011	13 <sup>th</sup> Annual Meeting of the European Federation of Autonomic Societies EFAS, Bern. Autonomic Failure in MSA: an update.
153	04.11.2011	1 <sup>st</sup> UK MSA research meeting, London
154	15.- 16.01.2012	EFNS/MDS-ES PD diagnosis guideline Editorial Meeting, Rom
155	19.03.2012	4 <sup>th</sup> International Congress on Multiple System Atrophy, Toulouse. Update on EMSA cohort.

7. Invited national Talks		
1	23.03.1995	Univ.-Klinik für Neurologie, Innsbruck. Ein Neurotransplantationsmodell der Multisystematrophie.
2	20.05.1995	Univ.-Klinik für Neurologie, Innsbruck. Symposium Morbus Parkinson: Atypische Parkinson-Syndrome.
3	09.06.1995	Jahrestagung der Österreichischen Parkinson-Gesellschaft, Graz. Differentialdiagnose der atypischen Parkinson-Syndrome.
4	02.03.1996	Wissenschaftliche Tagung der Österreichischen Parkinson Gesellschaft, Seefeld. Multisystematrophie.
5	30.01.1997	Landeskrankenhaus St. Pölten. Atypische Parkinsonsyndrome: Aktuelle klinische und therapeutische Aspekte.
6	25.05.1997	Jahrestreffen Österreichische Parkinson Gesellschaft, Wiener Neustadt. Progression des idiopathischen Parkinsonsyndroms mit sozioökonomischem und psychosozialen Outcome.
7	26.3.1998	Jahrestreffen Österreichische Parkinson Gesellschaft, Wien. Differentialdiagnose des Parkinsonsyndroms
8	01.10.1998	1. Gemeinsame Jahrestagung der österreichischen, deutschen und schweizerischen Gesellschaften für Neurorehabilitation, Innsbruck. Krankheitsprogression und –behinderung beim idiopathischen

		Parkinsonsyndrom.
9	26.03.1999	Jahrestagung der Österreichischen Parkinson-Gesellschaft, Graz. Epidemiologie des Parkinsonsyndroms.
10	18.11.1999	33. Tagung der Österreichischen Gesellschaft für Tropenmedizin und Parasitologie, Innsbruck. Neurotoxine in der dritten Welt am Beispiel „Sugar cane poisoning“ und Mangan-induziertes Parkinsonsyndrom.
11	18.11.1999	33. Tagung der Österreichischen Gesellschaft für Tropenmedizin und Parasitologie, Innsbruck. Epidemiologie der Parkinsonsyndrome in den Tropen.
12	10.11.2000	4. Internationale EPDA Konferenz, Wien. Management of sexual dysfunction in Parkinson`s Disease.
13	13.01.2001	Symposium City Club, Wien. Amantadine in der Behandlung L-Dopa-induzierter Dyskinesien.
14	16.05.2001	Fortbildungsvortrag an der Universitätsklinik für Neurologie, Graz. Multisystematrophien.
15	16.06.2001	2. Parkinson-Symposium, Rügen. Differentialdiagnose des Parkinson-Syndroms.
16	06.07.2001	Facharztausbildungsseminar der Österreichischen Gesellschaft für Neurologie, Neurogeriatrie, Innsbruck. Parkinsonsyndrome, Gangstörungen und Stürze.
17	07.07.2001	1. Neuroimaging-Workshop, Bad Tatzmannsdorf. Differentialdiagnostik der Parkinson-Syndrome – Klinische Probleme.
18	03.09.2001	7 <sup>th</sup> Meeting of the Austrian Neuroscience Association (ANA), Schloss Seggau. Multiple system atrophy.
19	08.11.2001	Basalganglienfortbildung Graz, „Parkinson-Tag“
20	01.12.2001	West-Geriatrie-Seminar 3, Diplomfortbildungskurs Geriatrie der Österr. Ärztekammer, Innsbruck. Extrapiramidal-motorische Erkrankungen im Alter.
21	12.03.2002	Fortbildungsveranstaltung Christian Doppler Klinik Salzburg. Morbus Huntington.
22	10.- 11.09.2002	3. Arbeitsgruppentreffen ArGe APS ÖPG, Pörtschach. Management atypischer Parkinson-Syndrome.
23	27.- 28.10.2002	EFNS Wien. Recent advances in Movement disorders. Update on multiple system atrophy.
24	29.- 30.11.2002	IV. Update in Neurologie, Wien. Praktische Diagnostik der Parkinsonsyndrome.
25	19.- 22.03.2003	1. Jahrestagung der Österreichischen Gesellschaft für Neurologie, Innsbruck. VS 1 Videoseminar Bewegungsstörungen. Pathogenese der Parkinson-Krankheit: Ansätze für neue Therapiestrategien.
26	05.06.2003	Jahrestagung der Österreichischen Parkinson Gesellschaft, Linz. Neurotransplantation bei Mb. Parkinson. UMSARS.
27	05.07.2003	IWOP Interaktiver Workshop, Seefeld. Diagnostik beim Mb. Parkinson und Abgrenzung von verwandten Syndromen.
28	04.10.2003	ÖGNER Jahrestagung, Hochzirl
29	15.11.2003	Jahrestagung der Österreichischen Gesellschaft für klinische Neurophysiologie, Wien. Dysautonomie bei MSA und anderen atypischen Parkinson-Syndromen.
30	20.11.2003	Institut für Neurowissenschaften, Innsbruck. Neurodegenerative diseases.
31	18.12.2003	Institut für Pharmakologie, Innsbruck. Basics of MSA.

32	22.04.2004	Facharztausbildungsseminar der Österreichischen Gesellschaft für Neurologie, Innsbruck. Parkinsonsyndrome, Gangstörungen und Stürze.
33	06.05.- 08.05.2004	Jahrestagung der Österreichischen Parkinson Gesellschaft, Pörtschach. Basalganglienclub.
34	22.- 23.10.2004	Symposium „Mental Dysfunction in Parkinson’s Disease, Salzburg. Amantadine in multiple system atrophy.
35	17.11.2004	Doctorate Program in Medical Science – Neuroscience, Innsbruck. Neurodegenerative disease.
36	13.01.2005	Konsensus-Meeting „Parkinson-Demenz“, Wien. Parkinson-Demenz versus Demenz mit Lewy Körperchen.
37	22.04.2005	ÖGN Jahrestagung, Graz. Videoseminar Bewegungsstörungen.
38	09.09.2005	Wagner Jauregg Nervenlinik Linz. Neuroanatomie und Pathophysiologie von Bewegungsstörungen.
39	13.01.2006	Parkinson Konsensus Meeting, Wien. Management der Wearing Off Symptomatik.
40	17.03.2006	ÖGN Jahrestagung, Wien. Moderation Videoseminar für Bewegungsstörungen.
41	16.06.2006	2 <sup>nd</sup> International Symposium on Parkinson’s Disease and Movement Disorders, Innsbruck. Interaktive Fallpräsentation.
42	12.01.2007	3 <sup>rd</sup> International Congress on Multiple System Atrophy, Innsbruck. Natural history and phenotypic variation of MSA.
43	03.02.2007	Neuroimaging in PD, Igl. Assessing progression with MRI - the MSA experience.
44	17.03.2007	8 <sup>th</sup> International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2007), Salzburg. PD, LBD and MSA: Animal Models and their Use in Therapeutic Strategies.
45	22.05.2007	BrainDays, Rust. Update: Lewy-Body-Demenz.
46	23.10.2007	Christian Doppler Klinik, Salzburg. Therapie-Update Mb. Parkinson: Rolle der kontinuierlichen dopaminergen Stimulation.
47	26.11.2007	Univ.-Klinik für Neurologie, Innsbruck. Diagnosing atypical parkinsonism - MSA,PSP,CBD.
49	06.02.2008	ÖGN Jahrestagung, Innsbruck. Ist Rasagiline neuroprotektiv? Präklinische Daten.
50	26.02.2008	Diplom-Fortbildung der Österreichischen Ärztekammer. Compliance in der Parkinsonbehandlung.
51	29.02.2008	Dopamine Transporter Imaging Workshop, Innsbruck. Diagnostic pitfalls in PD (clinical case presentation).
52	15.04.2008	Linz. Compliance in der Parkinsontherapie.
53	17.04.2008	Fortbildungsveranstaltung “Kunst als Brücke zur Welt“, Wien. MSA – eine behandelbare Erkrankung?
54	08.05.2008	BrainDays, Rust. Orthostatische Dysregulation - eine behandelbare Sturzursache. Parkinson Plus Syndrome.
55	14.05.2008	Bedside Teaching Courses, Innsbruck. Diagnostik und Therapie des Mb. Parkinson – Interaktives Fallseminar.
56	16.05.2008	8. Grazer Parkinsonstag, Graz. Therapie des L – Dopa Langzeit – Syndroms: Krankheitsmodifikation.
57	29.05.2008	Facharzt Ausbildungsseminar der ÖGN, Linz. Autonome Erkrankungen in der Neurologie: Neurodegenerative Erkrankungen und Erkrankungen des peripheren Nervensystems.

59	04.09.2008	Fortbildungsveranstaltung, Innsbruck. Diagnose und Behandlung der Alzheimer Demenz.
60	19.09.2008	21. Jahrestagung der ÖAG, Wien. Leitsymptom-orientierte Demenzdiagnostik: Leitsymptom Hypo-, Hyperkinesie.
61	23.09.2008	Diplom-Fortbildung der Österreichischen Ärztekammer, Innsbruck. Parkinson Demenz – Was gibt es Neues?
62	15.10.2008	Fortbildung “Synkopen und orthostatische Dysregulationen: Eine interdisziplinäre Herausforderung“, Innsbruck. Neurogene Synkopen.
63	12.11.2008	Facharzt Ausbildungsseminar, Innsbruck. Parkinsonsyndrome, Gangstörungen und Stürze.
64	14.11.2008	Jahrestagung 08 der ÖPG, Linz. Dopamin agonisten und kontinuierliche Plasmaspiegel: Wie wichtig ist die Dosierungsfrequenz?
65	14.01.2009	Neurologische Fortbildung KH, Kufstein. Neue Therapiemöglichkeiten der Parkinsonerkrankung.
66	24.- 25.03.2009	ÖGN-Jahrestagung, Villach. Aktivitäten der Arbeitsgruppe 2008.
67	14.01.2009	Fortbildungsveranstaltung, Kufstein. Neue Therapiemöglichkeiten der Parkinsonerkrankung.
68	16.06.2009	Vortrag: “Wiener Neustadt. Früherkennung und Frühtherapie bei Mb. Parkinson.
69	20.06.2009	Fortbildungsveranstaltung, Saalfelden. Grundlagen der Neuroprotektion.
70	25.08.2009	Fortbildungsveranstaltung in der Landesnervenklinik Wagner Jauregg, Linz. Kontinuierliche dopaminerge Stimulation in der Parkinson-Behandlung – Aktuelles aus der Stride-PD-Studie.
71	11.12.2009	Fortbildungsveranstaltung im Krankenhaus Göttlicher Heiland, Wien. Kontinuierliche dopaminerge Stimulation in der Parkinson-Behandlung – Aktuelles aus der Stride-PD-Studie.
72	15.12.2009	Fortbildungsveranstaltung im Landeskrankenhaus Waldviertel, Horn. Kontinuierliche dopaminerge Stimulation in der Parkinson-Behandlung – Aktuelles aus der Stride-PD-Studie.
73	15.01.2010	Innsbrucker Neurologie Kurs 2010, Innsbruck. Atypische Parkinson-Syndrome – klinische Hinweiszeichen und sinnvoller Einsatz von Zusatzdiagnostik bei Verdacht auf MSA, PSP oder CBD. Management der nicht-motorischen Symptome des Morbus Parkinson.
74	25.02.2010	8. Jahrestagung der ÖGN, Linz. Diagnostik und Therapie autonomer Störungen bei neurodegenerativen Erkrankungen.
75	03.03.2010	Demenz-Update, Innsbruck. Aktuelles zur Diagnose der Alzheimer Demenz.
76	11.03.2010	27. Ernährungskongress des Verbandes der Diätologen Österreichs, Wien. Appetitregulationsstörungen in der Neurologie.
77	23.03.2010	Fortbildung der Österreichischen Ärztekammer, Innsbruck. Demenztherapie 2010 – Stellenwert von Memantine
78	12.06.2010	4. Waldviertler Neurologiefrühling, Horn. Neuroprotektion bei Morbus Parkinson: Realität?
79	26.06.2010	Fortbildungsveranstaltung “Parkinson’s Disease: Theory and Practice“ Medizinische Universität Innsbruck. Treatment of PD: Advanced stages, motor complications.
80	14.10.2010	Fortbildungsveranstaltung BKH Linz. Krankheitsmodifikation: eine innovative neurologische Therapie-Strategie.

81	15.09.2010	Parkinson-Informationsveranstaltung, Wolfurt. Neue Arzneimittel in der Parkinson-Therapie: Wirkungen und Studienergebnisse.
82	21.10.2010	Jahrestagung der ÖPG, Wien. Therapieansätze bei atypischen Parkinson-Erkrankungen.
83	16.03.2011	Arbeitsgruppensitzung im Rahmen der 9. Jahrestagung der ÖGN, Wien
84	30.03.2011	ÖPG Industrierundtisch, Wien
85	11.05.2011	Landesnervenklinik Wagner-Jauregg, Linz. Demenztherapie 2011 – Stellenwert von Memantin.
86	04.07.2011	Abteilung Neurologie und Psychiatrie, AKH, Linz. DLB Update mit der Aarslandstudie.
87	17.09.2011	24. Jahrestagung der ÖAG, Rosenberg
88	19.10.2011	Parkinson-Informationsveranstaltung, Wolfurt. Parkinson-Therapie: Update.
89	24.02.2012	MDS-ES Winter School, Innsbruck. Clinical presentation of atypical parkinsonism.
90	10.03.2012	6 <sup>th</sup> World Congress on Controversies in Neurology, Wien. Are MSA and PD distinct clinical entities?
91	13.03.2012	Bundesrealgymnasium in der Au, Innsbruck. Leistungssteigerung des Gehirns (elektronisch, biochemisch).
92	14.03.2012	Arbeitsgruppensitzung im Rahmen der 10. Jahrestagung der ÖGN, Graz

<b>8. Grants</b>		
1992-1994	Dreijähriges Forschungsstipendium der englischen Parkinson Gesellschaft, London	<b>119.550 €</b>
1994-1997	Neurotransplantationsmodell der MSA, FWF Projekt P11748 MED	<b>142.440 €</b>
1995-1996	Clinical investigations of nicotine in Parkinson`s disease, VERUM-Stiftung, BRD	<b>45.780 €</b>
1997	Wirksamkeit und Verträglichkeit eines Nikotin-Pflasters bei M. Parkinson: eine doppelblinde Cross-Over Studie (VERUM Stiftung)	<b>50.000 €</b>
1997-1998	Parkinson-Tiermodelle, Forschungsstipendium der österreichischen Parkinson-Gesellschaft	<b>5.090 €</b>
1999	Antidyskinetische Effekte von Amantadin bei M. Parkinson: eine doppelblinde Cross-Over Studie (Kolassa-Merz)	<b>2.000 €</b>
1999	Wirksamkeit und Verträglichkeit von Riluzol bei M. Huntington (AVENTIS Deutschland)	<b>4.000 €</b>
1999-2000	Experimental neuroregeneration and protection in an animal model of MSA, ONB Projekt 8298	<b>43.240 €</b>
1999-2003	Progression der striatonigralen Degeneration bei der MSA, Forschungsauftrag des BMWV 70038/2-Pr4/98	<b>170.420 €</b>
2000-2005	European MSA Study Group, EU Projekt QLRT-2000-00661	<b>543.363 €</b>
2002-2004	Neuroprotektion im Rattenmodell der MSA, FWF Projekt P14633-PHA	<b>150.070 €</b>
2003	Amantadin-Therapiestudie bei MSA (MSA Studiengruppe der Österreichischen Parkinson-Gesellschaft) (Kolassa-Merz)	<b>5.000 €</b>

2003	Neuroprotektive Effekte von Riluzol im MSA-P Rattenmodell (AVENTIS Deutschland)	5.000 €
2003	International Conference on Atypical Parkinsonian Disorders (MOVEMENT DISORDERS SOCIETY, AMERSHAM)	60.000 €
2003-2006	The role of alpha-synuclein in glial cells, FWF Projekt P16128-B01	189.992 €
2005-2006	Verhaltensphysiologie der L-Dopa Response im MSA-SND Modell, MFF Projekt	9.780 €
2006	Neuroprotection in MSA models: effects of rasagiline (TEVA)	60.000 €
2005-2008	MSA Neurotransplantation, FWF Projekt P17905-B05	216.772 €
2007	Autonomic failure in a MSA mouse model, TWF Projekt	4.000 €
2007	MSA Konsensuskriterien, NIH Projekt	35.000 €
2007-2010	Brain Repair in MSA, FWF Projekt DK-C34-B05	135.000 €
2007-2010	MSA and Neuroinflammation, FWF Projekt P19989-B05	241.752 €
2008	The role of dopaminergic stimulation on striatal graft survival and function in the MSA rat model, MFI Projekt 9441	65.000 €
2008-2010	Cell Fate Analysis of Embryonal and Adult Stem Cell-Derived Grafts in PD and MSA Models, IFTZ Projekt	285.960 €
2008	EMSA-SG Conference Napoli 02/2008 (Multiple sponsors)	35.000 €
2009	Neuroprotection in MSA models: effects of MPO inhibitors (ASTRA ZENECA)	75.000 €
2010	Neuroprotection in a mouse model of MSA: AZD (AstraZeneca)	142.500 €
2011-2012	Effekte der Neurotransplantation in einem optimierten Modell der MSA, TWF Projekt, GZ 29487	16.600 €
2010-2011	Krankheitsverlauf und Prognose der Multisystematrophie, ÖNB 13946	28.000 €
ab 2011	Functional read-outs and novel interventional targets in a transgenic MSA model, FWF SFB F44	364.790 €
	TOTAL	3.557.851 €

9. Publications	
<b>Originals</b>	
1	Wenning GK. Die Illuminationslehre Augustins. <i>Augustiniana</i> 1989;39:99-118.
2	Ludolph AC, Wenning GK, Masur H, Furatsch N, Elger CE. Electromagnetic stimulation of the nervous system. I. Normal values in the central nervous system and a comparison with electric stimulation. <i>EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb.</i> 1989 Sep;20(3):153-8.
3	Wenning G. Der Einfluß des Manichäismus und des Ambrosius auf die Hermeneutik Augustins. <i>Revue des Etudes Augustiniennes</i> 1990, 36:80-90.
4	Wenning GK, Shephard B, Magalhaes M, Hawkes CH, Quinn NP. Olfactory function in multiple system atrophy. <i>Neurodegeneration</i> 1993, 2:169-171.
5	Wenning GK, Quinn N, Magalhaes M, Mathias C, Daniel SE. "Minimal change" multiple system atrophy. <i>Mov Disord.</i> 1994 Mar;9(2):161-6.



6	Wenning GK, Wietholter H, Schnauder G, Muller PH, Kanduth S, Renn W. Recovery of the hypothalamic-pituitary-adrenal axis from suppression by short-term, high-dose intravenous prednisolone therapy in patients with MS. <u><i>Acta Neurol Scand.</i> 1994 Apr;89(4):270-3.</u>
7	Wenning GK, Jager R, Kendall B, Kingsley D, Daniel SE, Quinn NP. Is cranial computerized tomography useful in the diagnosis of multiple system atrophy? <u><i>Mov Disord.</i> 1994 May;9(3):333-6.</u>
8	Wenning GK, Ben-Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. <u><i>Brain.</i> 1994 Aug;117 ( Pt 4):835-45.</u>
9	Klein C, Wenning GK, Quinn NP. Pseudotransitory ischemic attacks as the initial symptom of multiple system atrophy. <u><i>Nervenarzt.</i> 1995 Feb;66(2):133-5.</u>
10	Wenning GK, Ben-Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinicopathological study of 35 cases of multiple system atrophy. <u><i>J Neurol Neurosurg Psychiatry.</i> 1995 Feb;58(2):160-6.</u>
11	Davie CA, Wenning GK, Barker GJ, Tofts PS, Kendall BE, Quinn NP, McDonald WI, Marsden CD, Miller DH. Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. <u><i>Ann Neurol.</i> 1995 Feb;37(2):204-10.</u>
12	Magalhaes M, Wenning GK, Daniel SE, Quinn NP. Autonomic dysfunction in pathologically confirmed multiple system atrophy and idiopathic Parkinson's disease--a retrospective comparison. <u><i>Acta Neurol Scand.</i> 1995 Feb;91(2):98-102.</u>
13	Wenning GK, Shephard B, Hawkes C, Petruckevitch A, Lees A, Quinn NP. Olfactory function in atypical parkinsonian syndromes. <u><i>Acta Neurol Scand.</i> 1995 Apr;91(4):247-50.</u>
14	Plante-Bordeneuve V, Bandmann O, Wenning GK, Quinn NP, Daniel SE, Harding AE. CYP2D6-debrisoquine hydroxylase gene polymorphism in multiple system atrophy. <u><i>Mov Disord.</i> 1995 May;10(3):277-8.</u>
15	Pramstaller PP, Wenning GK, Smith SJ, Beck RO, Quinn NP, Fowler CJ. Nerve conduction studies, skeletal muscle EMG, and sphincter EMG in multiple system atrophy. <u><i>J Neurol Neurosurg Psychiatry.</i> 1995 May;58(5):618-21.</u>
16	Wenning GK, O'Connell MT, Patsalos PN, Quinn NP. A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease. <u><i>Mov Disord.</i> 1995 Sep;10(5):664-7.</u>
17	Granata R, Wenning GK, Jolkkonen J, Jenner P, Marsden CD. Effect of repeated administration of dopamine agonists on striatal neuropeptide mRNA expression in rats with a unilateral nigral 6-hydroxydopamine lesion. <u><i>J Neural Transm.</i> 1996;103(3):249-60.</u>
18	Tison F, Wenning GK, Volonte MA, Poewe WR, Henry P, Quinn NP. Pain in multiple system atrophy. <u><i>J Neurol.</i> 1996 Feb;243(2):153-6.</u>
19	Wenning GK, Tison F, Elliott L, Quinn NP, Daniel SE. Olivopontocerebellar pathology in multiple system atrophy. <u><i>Mov Disord.</i> 1996 Mar;11(2):157-62.</u>
20	Klein C, Wenning GK, Quinn NP, Marsden CD. Ataxia without telangiectasia masquerading as benign hereditary chorea. <u><i>Mov Disord.</i> 1996 Mar;11(2):217-20.</u>
21	Litvan I, Agid Y, Jankovic J, Goetz CG, Brandel JP, Lai EC, Wenning G, D'Olhaberriague L, Verny M, Chaudhuri KR, McKee A, Jellinger K, Bartko JJ, Mangone CA, Pearce RK. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). <u><i>Neurology.</i> 1996 Apr;46(4):922-30.</u>
22	Wenning GK, Granata R, Laboyrie PM, Quinn NP, Jenner P, Marsden CD. Reversal of

	behavioural abnormalities by fetal allografts in a novel rat model of striatonigral degeneration. <u><i>Mov Disord.</i> 1996 Sep;11(5):522-32.</u>
23	Wenning GK, Kraft E, Beck R, Fowler CJ, Mathias CJ, Quinn NP, Harding AE. Cerebellar presentation of multiple system atrophy. <u><i>Mov Disord.</i> 1997 Jan;12(1):115-7.</u>
24	Wenning GK, Jellinger K, Litvan I. Supranuclear gaze palsy and eyelid apraxia in postencephalitic parkinsonism. <u><i>J Neural Transm.</i> 1997;104(8-9):845-65.</u>
25	Ben-Shlomo Y, Wenning GK, Tison F, Quinn NP. Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. <u><i>Neurology.</i> 1997 Feb;48(2):384-93.</u>
26	Wenning GK, Tison F, Ben-Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. <u><i>Mov Disord.</i> 1997 Mar;12(2):133-47.</u>
27	Donnemiller E, Heilmann J, Wenning GK, Berger W, Decristoforo C, Moncayo R, Poewe W, Ransmayr G. Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. <u><i>Eur J Nucl Med.</i> 1997 Mar;24(3):320-5.</u>
28	Gu M, Gash MT, Cooper JM, Wenning GK, Daniel SE, Quinn NP, Marsden CD, Schapira AH. Mitochondrial respiratory chain function in multiple system atrophy. <u><i>Mov Disord.</i> 1997 May;12(3):418-22.</u>
29	Wenning GK, Smith SJ. Magnetic brain stimulation in multiple system atrophy. <u><i>Mov Disord.</i> 1997 May;12(3):452-3.</u>
30	Litvan I, Agid Y, Sastry N, Jankovic J, Wenning GK, Goetz CG, Verny M, Brandel JP, Jellinger K, Chaudhuri KR, McKee A, Lai EC, Pearce RK, Bartko JJ. What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study. <u><i>Neurology.</i> 1997 Jul;49(1):62-9. Erratum in: <i>Neurology</i> 1997 Dec;49(6):1755.</u>
31	Klein C, Brown R, Wenning G, Quinn N. The "cold hands sign" in multiple system atrophy. <u><i>Mov Disord.</i> 1997 Jul;12(4):514-8.</u>
32	Wenning GK, Odin P, Morrish P, Rehncrona S, Widner H, Brundin P, Rothwell JC, Brown R, Gustavii B, Hagell P, Jahanshahi M, Sawle G, Björklund A, Brooks DJ, Marsden CD, Quinn NP, Lindvall O. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. <u><i>Ann Neurol.</i> 1997 Jul;42(1):95-107.</u>
33	Litvan I, Goetz CG, Jankovic J, Wenning GK, Booth V, Bartko JJ, McKee A, Jellinger K, Lai EC, Brandel JP, Verny M, Chaudhuri KR, Pearce RK, Agid Y. What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. <u><i>Arch Neurol.</i> 1997 Aug;54(8):937-44.</u>
34	Bandmann O, Sweeney MG, Daniel SE, Wenning GK, Quinn N, Marsden CD, Wood NW. Multiple-system atrophy is genetically distinct from identified inherited causes of spinocerebellar degeneration. <u><i>Neurology.</i> 1997 Dec;49(6):1598-604.</u>
35	Litvan I, Booth V, Wenning GK, Bartko JJ, Goetz CG, McKee A, Jankovic J, Jellinger K, Lai EC, Brandel JP, Verny M, Chaudhuri KR, Pearce RK, Agid Y. Retrospective application of a set of clinical diagnostic criteria for the diagnosis of multiple system atrophy. <u><i>J Neural Transm.</i> 1998;105(2-3):217-27.</u>
36	Wenning GK, Litvan I, Jankovic J, Granata R, Mangone CA, McKee A, Poewe W, Jellinger K, Chaudhuri KR, D'Olhaberriague L, Pearce RK. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. <u><i>J Neurol Neurosurg Psychiatry.</i> 1998 Feb;64(2):184-9.</u>
37	Wenning GK, Donnemiller E, Granata R, Riccabona G, Poewe W. 123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease. <u><i>Mov Disord.</i> 1998 May;13(3):438-45.</u>

38	Litvan I, MacIntyre A, Goetz CG, Wenning GK, Jellinger K, Verny M, Bartko JJ, Jankovic J, McKee A, Brandel JP, Chaudhuri KR, Lai EC, D'Olhaberriague L, Pearce RK, Agid Y. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. <u><i>Arch Neurol.</i> 1998 Jul;55(7):969-78.</u>
39	Wenning GK, Litvan I, Verny M, Chaudhuri KR, Granata R, Poewe W, Jellinger K. Is EEG useful in the differential diagnosis of parkinsonism? <u><i>Parkinsonism Rel Disord</i> 1998 Aug, 4(2):79-80.</u>
40	Litvan I, Jankovic J, Goetz CG, Wenning GK, Sastry N, Jellinger K, McKee A, Lai EC, Brandel JP, Verny M, Chaudhuri KR, Pearce RK, Bartko JJ, Agid Y. Accuracy of the clinical diagnosis of postencephalitic parkinsonism: a clinicopathologic study. <u><i>Eur J Neurol.</i> 1998 Sep;5(5):451-7.</u>
41	Klockgether T, Bürk K, Wüllner U, Wenning G, Schulz JB, Döller G, Wessel K, Huss P, Krämer A, Lüdtke R. Risk factors for idiopathic cerebellar ataxia of late onset. <u><i>J Neurol Sci.</i> 1998 Oct 8;160(2):171-4.</u>
42	Kronenberg MF, Menzel HJ, Ebersbach G, Wenning GK, Luginger E, Gollner M, Ransmayr G, Utermann G, Poewe W, Kronenberg F. Dopamine D4 receptor polymorphism and idiopathic Parkinson's disease. <u><i>Eur J Hum Genet.</i> 1999 Apr;7(3):397-400.</u>
43	Hagell P, Schrag A, Piccini P, Jahanshahi M, Brown R, Rehncrona S, Widner H, Brundin P, Rothwell JC, Odin P, Wenning GK, Morrish P, Gustavii B, Björklund A, Brooks DJ, Marsden CD, Quinn NP, Lindvall O. Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. <u><i>Brain.</i> 1999 Jun;122( Pt 6):1121-32.</u>
44	Bonifati V, Joosse M, Nicholl DJ, Vanacore N, Bennett P, Rizzu P, Fabbrini G, Marconi R, Colosimo C, Locuratolo N, Stocchi F, Bonuccelli U, de Mari M, Wenning G, Vieregge P, Oostra B, Meco G, Heutink P. The tau gene in progressive supranuclear palsy: exclusion of mutations in coding exons and exon 10 splice sites, and identification of a new intronic variant of the disease-associated H1 haplotype in Italian cases. <u><i>Neurosci Lett.</i> 1999 Oct;274(1):61-5.</u>
45	Wenning GK, Ebersbach G, Verny M, Chaudhuri KR, Jellinger K, McKee A, Poewe W, Litvan I. Progression of falls in postmortem-confirmed parkinsonian disorders. <u><i>Mov Disord.</i> 1999 Nov;14(6):947-50.</u>
46	Ebersbach G, Stöck M, Müller J, Wenning G, Wissel J, Poewe W. Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration. <u><i>Mov Disord.</i> 1999 Nov;14(6):1011-3.</u>
47	Wenning GK, Scherfler C, Granata R, Bösch S, Verny M, Chaudhuri KR, Jellinger K, Poewe W, Litvan I. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. <u><i>J Neurol Neurosurg Psychiatry.</i> 1999 Nov;67(5):620-3.</u>
48	Puschban Z, Scherfler C, Granata R, Laboyrie P, Quinn NP, Jenner P, Poewe W, Wenning GK. Autoradiographic study of striatal dopamine re-uptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or co-grafts. <u><i>Neuroscience.</i> 2000;95(2):377-88.</u>
49	Scherfler C, Puschban Z, Ghorayeb I, Goebel GP, Tison F, Jellinger K, Poewe W, Wenning GK. Complex motor disturbances in a sequential double lesion rat model of striatonigral degeneration (multiple system atrophy). <u><i>Neuroscience.</i> 2000;99(1):43-54.</u>
50	Wenning GK, Jellinger KJ, Quinn NP, Poewe WH. An early report of striatonigral

	degeneration. <u><i>Mov Disord.</i> 2000 Jan;15(1):159-62.</u>
51	Wenning GK, Ben-Shlomo Y, Hughes A, Daniel SE, Lees A, Quinn NP. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? <u><i>J Neurol Neurosurg Psychiatry.</i> 2000 Apr;68(4):434-40.</u>
52	Ghorayeb I, Fernagut PO, Aubert I, Bezard E, Poewe W, Wenning GK, Tison F. Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration. <u><i>Mov Disord.</i> 2000 May;15(3):531-6.</u>
53	Puschban Z, Waldner R, Seppi K, Stefanova N, Humpel C, Scherfler C, Levivier M, Poewe W, Wenning GK. Failure of neuroprotection by embryonic striatal grafts in a double lesion rat model of striatonigral degeneration (multiple system atrophy). <u><i>Exp Neurol.</i> 2000 Jul;164(1):166-75.</u>
54	Schocke MF, Waldner R, Puschban Z, Kolbitsch C, Seppi K, Scherfler C, Kremser C, Zschiegner F, Felber S, Poewe W, Wenning GK. In vivo magnetic resonance imaging of embryonic neural grafts in a rat model of striatonigral degeneration (multiple system atrophy). <u><i>Neuroimage.</i> 2000 Aug;12(2):209-18.</u>
55	Luginger E, Wenning GK, Bösch S, Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. <u><i>Mov Disord.</i> 2000 Sep;15(5):873-8.</u>
56	Donnemiller E, Brenneis C, Wissel J, Scherfler C, Poewe W, Riccabona G, Wenning GK. Impaired dopaminergic neurotransmission in patients with traumatic brain injury: a SPECT study using 123I-beta-CIT and 123I-IBZM. <u><i>Eur J Nucl Med.</i> 2000 Sep;27(9):1410-4.</u>
57	Müller J, Wenning GK, Jellinger K, McKee A, Poewe W, Litvan I. Progression of Hoehn and Yahr stages in Parkinsonian disorders: a clinicopathologic study. <u><i>Neurology.</i> 2000 Sep;55(6):888-91.</u>
58	Kofler M, Muller J, Reggiani L, Wenning GK. Somatosensory evoked potentials in progressive supranuclear palsy. <u><i>J Neurol Sci.</i> 2000 Oct;179(S 1-2):85-91.</u>
59	Waldner R, Puschban Z, Scherfler C, Seppi K, Jellinger K, Poewe W, Wenning GK. No functional effects of embryonic neuronal grafts on motor deficits in a 3-nitropropionic acid rat model of advanced striatonigral degeneration (multiple system atrophy). <u><i>Neuroscience.</i> 2001;102(3):581-92.</u>
60	Kofler M, Müller J, Wenning GK, Reggiani L, Hollosi P, Bösch S, Ransmayr G, Valls-Sole J, Poewe W. The auditory startle reaction in parkinsonian disorders. <u><i>Mov Disord.</i> 2001 Jan;16(1):62-71.</u>
61	Ghorayeb I, Puschban Z, Fernagut PO, Scherfler C, Rouland R, Wenning GK, Tison F. Simultaneous intrastriatal 6-hydroxydopamine and quinolinic acid injection: a model of early-stage striatonigral degeneration. <u><i>Exp Neurol.</i> 2001 Jan;167(1):133-47.</u>
62	Müller J, Wenning GK, Verny M, McKee A, Chaudhuri KR; Jellinger K, Poewe W, Litvan I. Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. <u><i>Arch Neurol.</i> 2001 Feb;58(2):259-64.</u>
63	Müller J, Wissel J, Masuhr F, Ebersbach G, Wenning GK, Poewe W. Clinical characteristics of the geste antagoniste in cervical dystonia. <u><i>J Neurol.</i> 2001 Jun;248(6):478-82.</u>
64	Stefanova N, Klimaschewski L, Poewe W, Wenning GK, Reindl M. Glial cell death induced by overexpression of alpha-synuclein. <u><i>J Neurosci Res.</i> 2001 Sep;65(5):432-8.</u>
65	Seppi K, Mueller J, Bodner T, Brandauer E, Benke T, Weirich-Schwaiger H, Poewe W, Wenning GK. Riluzole in Huntington's disease (HD): an open label study with one year follow up. <u><i>J Neurol.</i> 2001 Oct;248(10):866-9.</u>
66	Ransmayr G, Seppi K, Donnemiller E, Luginger E, Marksteiner J, Riccabona G, Poewe W, Wenning GK. Striatal dopamine transporter function in dementia with Lewy bodies

	and Parkinson's disease. <i>Eur J Nucl Med.</i> 2001 Oct;28(10):1523-8.
67	Högl B, Seppi K, Brandauer E, Wenning G, Poewe W. Irresistible onset of sleep during acute levodopa challenge in a patient with multiple system atrophy (MSA): placebo-controlled, polysomnographic case report. <i>Mov Disord.</i> 2001 Nov;16(6):1177-9.
68	Fernagut PO, Diguët E, Stefanova N, Biran M, Wenning GK, Canioni P, Bioulac B, Tison F. Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: behavioural and histopathological characterisation. <i>Neuroscience.</i> 2002;114(4):1005-17.
69	Müller J, Wenning GK, Wissel J, Baldauf A, Seppi K, Brenneis C, Poewe W. Riluzole therapy in cervical dystonia. <i>Mov Disord.</i> 2002 Jan;17(1):198-200.
70	Ebersbach G, Sojer M, Müller J, Ransmayr G, Wenning G, Poewe W. Dysequilibrium in idiopathic Parkinson disease. The effect of cerebrovascular comorbidity. <i>Nervenarzt.</i> 2002 Feb;73(2):162-5.
71	Schocke MF, Seppi K, Esterhammer R, Kremser C, Jaschke W, Poewe W, Wenning GK. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. <i>Neurology.</i> 2002 Feb;58(4):575-80.
72	Bösch SM, Wenning GK, Ransmayr G, Poewe W. Dystonia in multiple system atrophy. <i>J Neurol Neurosurg Psychiatry.</i> 2002 Mar;72(3):300-3.
73	Müller J, Wenning GK, Wissel J, Seppi K, Poewe W. Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. <i>J Neurol.</i> 2002 Mar;249(3):300-4.
74	Wenning GK, Seppi K, Tison F, Jellinger K. A novel grading scale for striatonigral degeneration (multiple system atrophy). <i>J Neural Transm.</i> 2002 Mar;109(3):307-20.
75	Jellinger KA, Seppi K, Wenning GK, Poewe W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. <i>J Neural Transm.</i> 2002 Mar;109(3):329-39.
76	Stefanova N, Emgard M, Klimaschewski L, Wenning GK, Reindl M. Ultrastructure of alpha-synuclein-positive aggregations in U373 astrocytoma and rat primary glial cells. <i>Neurosci Lett.</i> 2002 Apr 19;323(1):37-40.
77	Tison F, Yekhlef F, Chrysostome V, Balestre E, Quinn NP, Poewe W, Wenning GK. Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease. <i>Mov Disord.</i> 2002 Jul;17(4):701-9.
78	Müller J, Kemmler G, Wissel J, Schneider A, Voller B, Grossmann J, Diez J, Homann N, Wenning GK, Schnider P, Poewe W; Austrian Botulinum Toxin and Dystonia Study Group. The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. <i>J Neurol.</i> 2002 Jul;249(7):842-6.
79	Scherfler C, Donnemiller E, Schocke M, Dierkes K, Decristoforo C, Oberladstätter M, Kolbitsch C, Zschiegner F, Riccabona G, Poewe W, Wenning G. Evaluation of striatal dopamine transporter function in rats by in vivo beta-[123I]CIT pinhole SPECT. <i>Neuroimage.</i> 2002 Sep;17(1):128-41.
80	Müller J, Seppi K, Stefanova N, Poewe W, Litvan I, Wenning GK. Freezing of gait in postmortem-confirmed atypical parkinsonism. <i>Mov Disord.</i> 2002 Sep;17(5):1041-5.
81	Müller J, Kiechl S, Wenning GK, Seppi K, Willeit J, Gasperi A, Wissel J, Gasser T, Poewe W. The prevalence of primary dystonia in the general community. <i>Neurology.</i> 2002 Sep;59(6):941-3.
82	Tison F, Yekhlef F, Balestre E, Chrysostome V, Quinn N, Wenning GK, Poewe W. Application of the International Cooperative Ataxia Scale rating in multiple system atrophy. <i>Mov Disord.</i> 2002 Nov;17(6):1248-54.

83	Osaki Y, Wenning GK, Daniel SE, Hughes A, Lees AJ, Mathias CJ, Quinn N. Do published criteria improve clinical diagnostic accuracy in multiple system atrophy? <i>Neurology</i> . 2002 Nov;59(10):1486-91.
84	Högl B, Saletu M, Brandauer E, Glatzl S, Frauscher B, Seppi K, Ulmer H, Wenning G, Poewe W. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. <i>Sleep</i> . 2002 Dec;25(8):905-9.
85	Ghorayeb I, Fernagut PO, Stefanova N, Wenning GK, Bioulac B, Tison F. Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine+3-nitropropionic acid model of striatonigral degeneration in monkeys. <i>Neurosci Lett</i> . 2002 Dec;335(1):34-8.
86	Högl B, Seppi K, Brandauer E, Glatzl S, Frauscher B, Niedermüller U, Wenning G, Poewe W. Increased daytime sleepiness in Parkinson's disease: a questionnaire survey. <i>Mov Disord</i> . 2003 Mar;18(3):319-23.
87	Kofler M, Müller J, Seppi K, Wenning GK. Exaggerated auditory startle responses in multiple system atrophy: a comparative study of parkinson and cerebellar subtypes. <i>Clin Neurophysiol</i> . 2003 Mar;114(3):541-7.
88	Seppi K, Schocke MF, Esterhammer R, Kremser C, Brenneis C, Müller J, Bösch S, Jaschke W, Poewe W, Wenning GK. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. <i>Neurology</i> . 2003 Mar;60(6):922-7.
89	Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, Quinn N, Sethi KD, Shults C, Wenning GK; Movement Disorders Society Scientific Issues Committee. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. <i>Mov Disord</i> . 2003 May;18(5):467-86.
90	Stefanova N, Schanda K, Klimaschewski L, Poewe W, Wenning GK, Reindl M. Tumor necrosis factor-alpha-induced cell death in U373 cells overexpressing alpha-synuclein. <i>J Neurosci Res</i> . 2003 Aug;73(3):334-40.
91	Stefanova N, Puschban Z, Fernagut PO, Brouillet E, Tison F, Reindl M, Jellinger KA, Poewe W, Wenning GK. Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy). <i>Acta Neuropathol (Berl)</i> . 2003 Aug;106(2):157-66.
92	Wenning GK, Geser F, Stampfer-Kountchev M, Tison F. Multiple system atrophy: an update. <i>Mov Disord</i> . 2003 Sep;18(Suppl 6):S34-42.
93	Brenneis C, Seppi K, Schocke MF, Müller J, Luginger E, Bösch S, Löscher WN, Büchel C, Poewe W, Wenning GK. Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy. <i>Mov Disord</i> . 2003 Oct;18(10):1132-8.
94	Brenneis C, Bösch SM, Schocke M, Wenning GK, Poewe W. Atrophy pattern in SCA2 determined by voxel-based morphometry. <i>Neuroreport</i> . 2003 Oct;14(14):1799-802.
95	Müller J, Kofler M, Wenning GK, Seppi K, Valls-Sole J, Poewe W. Auditory startle response in cervical dystonia. <i>Mov Disord</i> . 2003 Dec;18(12):1522-6.
96	Osaki Y, Ben-Shlomo Y, Lees AJ, Daniel SE, Colosimo C, Wenning G, Quinn N. Accuracy of clinical diagnosis of progressive supranuclear palsy. <i>Mov Disord</i> . 2004 Feb;19(2):181-9.
97	Brenneis C, Seppi K, Schocke M, Benke T, Wenning GK, Poewe W. Voxel based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy. <i>J Neurol Neurosurg Psychiatry</i> . 2004 Feb;75(2):246-9.

98	Schocke MF, Seppi K, Esterhammer R, Kremser C, Mair KJ, Czermak BV, Jaschke W, Poewe W, Wenning GK. Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease. <i>Neuroimage</i> . 2004 Apr;21(4):1443-51.
99	Stefanova N, Lundblad M, Tison F, Poewe W, Cenci MA, Wenning GK. Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy). <i>Neurobiol Dis</i> . 2004 Apr;15(3):630-9.
100	Müller J, Wissel J, Kemmler G, Voller B, Bodner T, Schneider A, Wenning GK, Poewe W. Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument. <i>J Neurol Neurosurg Psychiatry</i> . 2004 May;75(5):749-53.
101	Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. <i>Circulation</i> . 2004 May;109(18):2175-80.
102	Frauscher B, Högl B, Maret S, Wolf E, Bransauer E, Wenning GK, Kronenberg MF, Kronenberg F, Tafti M, Poewe W. Association of daytime sleepiness with COMT polymorphism in patients with parkinson disease: a pilot study. <i>Sleep</i> . 2004 Jun;27(4):733-6.
103	Brenneis C, Wenning GK, Egger KE, Schocke M, Trieb T, Seppi K, Marksteiner J, Ransmayr G, Benke T, Poewe W. Basal forebrain atrophy is a distinctive pattern in dementia with Lewy bodies. <i>Neuroreport</i> . 2004 Aug;15(11):1711-4.
104	Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, Giladi N, Holloway RG, Moore CG, Wenning GK, Yahr MD, Seidl L; Movement Disorder Society Task Force Report on Rating Scales for Parkinson's Disease. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. <i>Mov Disord</i> . 2004 Sep;19(9):1020-8.
105	Stefanova N, Mitschnigg M, Ghorayeb I, Diguët E, Geser F, Tison F, Poewe W, Wenning GK. Failure of neuronal protection by inhibition of glial activation in a rat model of striatonigral degeneration. <i>J Neurosci Res</i> . 2004 Oct;78(1):87-91.
106	Peralta C, Werner P, Holl B, Kiechl S, Willeit J, Seppi K, Wenning G, Poewe W. Parkinsonism following striatal infarcts: incidence in a prospective stroke unit cohort. <i>J Neural Transm</i> . 2004 Oct;111(10-11):1473-83.
107	Bösch SM, Donnemiller E, Müller J, Seppi K, Weirich-Schwaiger H, Poewe W, Wenning GK. Abnormalities of dopaminergic neurotransmission in SCA2: a combined 123I-betaCIT and 123I-IBZM SPECT study. <i>Mov Disord</i> . 2004 Nov;19(11):1320-5.
108	Wenning GK, Tison F, Seppi K, Sampaio C, Diem A, Yekhleif F, Ghorayeb I, Ory F, Galitzky M, Scaravilli T, Bozi M, Colosimo C, Gilman S, Shults CW, Quinn NP, Rascol O, Poewe W; Multiple System Atrophy Study Group. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). <i>Mov Disord</i> . 2004 Dec;19(12):1391-402.
109	Seppi K, Schocke MF, Donnemiller E, Esterhammer R, Kremser C, Scherfler C, Diem A, Jaschke W, Wenning GK, Poewe W. Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease. <i>Mov Disord</i> . 2004 Dec;19(12):1438-45.
110	Wenning GK, on behalf of the Working Group on Atypical Parkinsonism of the Austrian Parkinson's Society. Placebo-Controlled Trial of Amantadine in Multiple-System Atrophy. <i>Clin Neuropharmacol</i> . 2005;28:225-7.
111	Stampfer-Kountchev, M.; Poewe, W.; Wenning, GK. The postural tachycardia

	syndrome (POTS). <i>Aktuelle Neurologie</i> . 2005;32(8):472-6.
112	Seppi K, Yekhle F, Diem A, Luginer-Wolf E, Müller J, Tison F, Quinn NP, Poewe W, Wenning GK. Progression of parkinsonism in multiple system atrophy. <i>J Neurol</i> . 2005 Jan;252(1):91-6.
113	Scherfler C, Scholz SW, Donnemiller E, Decristoforo C, Oberladstätter M, Stefanova N, Diederer E, Virgolini I, Poewe W, Wenning GK. Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats. <i>Neuroimage</i> . 2005 Feb;24(3):822-31.
114	Mantoan L, Stefanova N, Egger KE, Jellinger KA, Poewe W, Wenning GK. Failure of caspase inhibition in the double-lesion rat model of striatonigral degeneration (multiple system atrophy). <i>Acta Neuropathol (Berl)</i> . 2005 Feb;109(2):191-7.
115	Stefanova N, Reindl M, Neumann M, Haass C, Poewe W, Kahle PJ, Wenning GK. Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. <i>Am J Pathol</i> . 2005 Mar;166(3):869-76.
116	Diguet E, Fernagut PO, Scherfler C, Wenning G, Tison F. Effects of riluzole on combined MPTP + 3-nitropropionic acid-induced mild to moderate striatonigral degeneration in mice. <i>J Neural Transm</i> . 2005 May;112(5):613-31.
117	Högl B, Kiechl S, Willeit J, Saletu M, Frauscher B, Seppi K, Müller J, Rungger G, Gasperi A, Wenning G, Poewe W. Restless legs syndrome: a community-based study of prevalence, severity, and risk factors. <i>Neurology</i> . 2005 Jun;64(11):1920-4.
118	Scherfler C, Seppi K, Donnemiller E, Goebel G, Brenneis C, Virgolini I, Wenning GK, Poewe W. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. <i>Brain</i> . 2005 Jul;128(Pt 7):1605-12.
119	Jellinger KA, Seppi K, Wenning GK. Grading of neuropathology in multiple system atrophy: proposal for a novel scale. <i>Mov Disord</i> . 2005 Aug;20(Suppl 12):S29-36.
120	Stefanova N, Reindl M, Poewe W, Wenning GK. In vitro models of multiple system atrophy. <i>Mov Disord</i> . 2005 Aug;20(Suppl 12):S53-6.
121	Wenning GK, Geser F, Poewe W. Therapeutic strategies in multiple system atrophy. <i>Mov Disord</i> . 2005 Aug;20(Suppl 12):S67-76.
122	Scherfler C, Sather T, Diguet E, Stefanova N, Puschban Z, Tison F, Poewe W, Wenning GK. Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy). <i>J Neural Transm</i> . 2005 Aug;112(8):1025-33.
123	Kamm C, Healy DG, Quinn NP, Wullner U, Moller JC, Schols L, Geser F, Burk K, Borglum AD, Pellecchia MT, Tolosa E, del Sorbo F, Nilsson C, Bandmann O, Sharma M, Mayer P, Gasteiger M, Haworth A, Ozawa T, Lees AJ, Short J, Giunti P, Holinski-Feder E, Illig T, Wichmann HE, Wenning GK, Wood NW, Gasser T; European Multiple System Atrophy Study Group. The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group. <i>Brain</i> . 2005 Aug;128(Pt 8):1855-60.
124	Berciano J, Wenning GK. The Lewis family revisited: no evidence for autosomal dominant multiple system atrophy. <i>Park Relat Disord</i> . 2005 Sep;11(6):363-5.
125	Wenning GK; Working Group on Atypical Parkinsonism of the Austrian Parkinson's Society. Placebo-controlled trial of amantadine in multiple-system atrophy. <i>Clin Neuropharmacol</i> . 2005 Sep-Oct;28(5):225-7.
126	Schmidauer C, Sojer M, Seppi K, Stockner H, Högl B, Biedermann B, Brandauer E, Peralta CM, Wenning GK, Poewe W. Transcranial ultrasound shows nigral



	hypoechoogenicity in restless legs syndrome. <i>Ann Neurol.</i> 2005 Oct;58(4):630-4.
127	Muller UJ, Frick B, Winkler C, Fuchs D, Wenning GK, Poewe W, Müller J. Homocysteine and serum markers of immune activation in primary dystonia. <i>Mov Disord.</i> 2005 Dec;20(12):1663-7.
128	Wenning GK, Kiechl S, Seppi K, Müller J, Högl B, Saletu M, Rungger G, Gasperi A, Willeit J, Poewe W. Prevalence of movement disorders in men and women aged 50-89 years (Bruneck Study cohort): a population-based study. <i>Lancet Neurol.</i> 2005 Dec;4(12):815-20.
129	Colosimo C, Gilman S, Quinn N, Wenning GK. Preface - Special issue: Multiple system atrophy. <i>J Neural Transm.</i> 2005 Dec;112(12):1601-3.
130	Puschban Z, Stefanova N, Petersen A, Winkler C, Brundin P, Poewe W, Wenning GK. Evidence for dopaminergic re-innervation by embryonic allografts in an optimized rat model of the Parkinsonian variant of multiple system atrophy. <i>Brain Res Bull.</i> 2005 Dec 15;68(1-2):54-8.
131	Brenneis C, Boesch SM, Egger KE, Seppi K, Scherfler C, Schocke M, Wenning GK, Poewe W. Cortical atrophy in the cerebellar variant of multiple system atrophy: a voxel-based morphometry study. <i>Mov Disord.</i> 2006 Feb;21(2):159-65.
132	Geser F, Wenning GK, Seppi K, Stampfer-Kountchev M, Scherfler C, Sawires M, Frick C, Ndayisaba JP, Ulmer H, Pellecchia MT, Barone P, Kim HT, Hooker J, Quinn NP, Cardozo A, Tolosa E, Abele M, Klockgether T, Ostergaard K, Dupont E, Schimke N, Eggert KM, Oertel W, Djaldetti R, Poewe W; the European MSA Study Group. Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). <i>Mov Disord.</i> 2006 Feb;21(2):179-86.
133	Scherfler C, Schocke MF, Seppi K, Esterhammer R, Brenneis C, Jaschke W, Wenning GK, Poewe W. Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. <i>Brain.</i> 2006 Feb;129(Pt 2):538-42.
134	Metzger S, Bauer P, Tomiuk J, Laccone F, Didonato S, Gellera C, Soliveri P, Lange HW, Weirich-Schwaiger H, Wenning GK, Melegh B, Havasi V, Baliko L, Wiczorek S, Arning L, Zaremba J, Sulek A, Hoffman-Zacharska D, Basak AN, Ersoy N, Zidovska J, Kebrdlova V, Pandolfo M, Ribai P, Kadasi L, Kvasnicova M, Weber BH, Kreuz F, Dose M, Stuhmann M, Riess O. The S18Y polymorphism in the UCHL1 gene is a genetic modifier in Huntington's disease. <i>Neurogenetics.</i> 2006 Mar;7(1):27-30.
135	Ozawa T, Healy DG, Abou-Sleiman PM, Ahmadi KR, Quinn N, Lees AJ, Shaw K, Wullner U, Berciano J, Moller JC, Kamm C, Burk K, Josephs KA, Barone P, Tolosa E, Goldstein DB, Wenning G, Geser F, Holton JL, Gasser T, Revesz T, Wood NW; European MSA Study Group. The alpha-synuclein gene in multiple system atrophy. <i>J Neurol Neurosurg Psychiatry.</i> 2006 Apr;77(4):464-7.
136	Seppi K, Schocke MF, Mair KJ, Esterhammer R, Scherfler C, Geser F, Kremser C, Boesch S, Jaschke W, Poewe W, Wenning GK. Progression of putaminal degeneration in multiple system atrophy: a serial diffusion MR study. <i>Neuroimage.</i> 2006 May 15;31(1):240-5.
137	Schrag A, Geser F, Stampfer-Kountchev M, Seppi K, Sawires M, Köllensperger M, Scherfler C, Quinn N, Pellecchia MT, Barone P, del Sorbo F, Albanese A, Ostergaard K, Dupont E, Cardozo A, Tolosa E, Nilsson CF, Widner H, Lindvall O, Giladi N, Gurevich T, Daniels C, Deuschl G, Coelho M, Sampaio C, Abele M, Klockgether T, Schimke N, Eggert KM, Oertel W, Djaldetti R, Colosimo C, Mecocci G, Poewe W, Wenning GK. Health-related quality of life in multiple system atrophy. <i>Mov Disord.</i> 2006 Jun;21(6):809-15.
138	Seppi K, Schocke MF, Prenschiuetz-Schuetzenau K, Mair KJ, Esterhammer R, Kremser C, Muigg A, Scherfler C, Jaschke W, Wenning GK, Poewe W. Topography of putaminal

	degeneration in multiple system atrophy: A diffusion magnetic resonance study. <u><i>Mov Disord.</i> 2006 Jun;21(6):847-52.</u>
139	Seppi K, Schocke MF, Mair KJ, Esterhammer R, Weirich-Schwaiger H, Utermann B, Egger K, Brenneis C, Granata R, Boesch S, Poewe W, Wenning GK. Diffusion-weighted imaging in Huntington's disease. <u><i>Mov Disord.</i> 2006 Jul;21(7):1043-7.</u>
140	Peralta C, Wolf E, Alber H, Seppi K, Müller S, Bösch S, Wenning GK, Pachinger O, Poewe W. Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study. <u><i>Mov Disord.</i> 2006 Aug;21(8):1109-13.</u>
141	Seppi K, Högl B, Diem A, Peralta C, Wenning GK, Poewe W. Levodopa-induced sleepiness in the Parkinson variant of multiple system atrophy. <u><i>Mov Disord.</i> 2006 Aug;21(8):1281-3.</u>
142	Geser F, Wenning GK. The diagnosis of multiple system atrophy. <u><i>J Neurol.</i> 2006 Aug;253 Suppl 3:iii2-iii15.</u>
143	Seppi K, Scherfler C, Donnemiller E, Virgolini I, Schocke MF, Goebel G, Mair KJ, Boesch S, Brenneis C, Wenning GK, Poewe W. Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [ <sup>123</sup> I]beta-CIT SPECT analysis. <u><i>Arch Neurol.</i> 2006 Aug;63(8):1154-60.</u>
144	Boesch SM, Frauscher B, Brandauer E, Wenning GK, Poewe W, Hogl B. Restless legs syndrome and motor activity during sleep in spinocerebellar ataxia type 6. <u><i>Sleep Med.</i> 2006 Sep;7(6):529-32.</u>
145	Metzger S, Bauer P, Tomiuk J, Laccone F, Didonato S, Gellera C, Mariotti C, Lange HW, Weirich-Schwaiger H, Wenning GK, Seppi K, Melegh B, Havasi V, Baliko L, Wieczorek S, Zaremba J, Hoffman-Zacharska D, Sulek A, Basak AN, Soydan E, Zidovska J, Kebrdlova V, Pandolfo M, Ribai P, Kadasi L, Kvasnicova M, Weber BH, Kreuz F, Dose M, Stuhmann M, Riess O. Genetic analysis of candidate genes modifying the age-at-onset in Huntington's disease. <u><i>Hum Genet.</i> 2006 Sep;120(2):285-92.</u>
146	Scherfler C, Boesch SM, Donnemiller E, Seppi K, Weirich-Schwaiger H, Goebel G, Virgolini I, Wenning GK, Poewe W. Topography of cerebral monoamine transporter availability in families with SCA2 mutations: a voxel-wise [(123)I]beta-CIT SPECT analysis. <u><i>Eur J Nucl Med Mol Imaging.</i> 2006 Sep;33(9):1084-90.</u>
147	Boesch SM, Frauscher B, Brandauer E, Wenning GK, Hogl B, Poewe W. Disturbance of rapid eye movement sleep in spinocerebellar ataxia type 2. <u><i>Mov Disord.</i> 2006 Oct;21(10):1751-4.</u>
148	Rinnerthaler M, Mueller J, Weichbold V, Wenning GK, Poewe W. Social stigmatization in patients with cranial and cervical dystonia. <u><i>Mov Disord.</i> 2006 Oct;21(10):1636-40.</u>
149	Seppi K, Peralta C, Diem-Zangerl A, Puschban Z, Mueller J, Poewe W, Wenning GK. Placebo-controlled trial of riluzole in multiple system atrophy. <u><i>Eur J Neurol.</i> 2006 Oct;13(10):1146-8.</u>
150	Hauser RA, Russ H, Haeger DA, Bruguere-Fontenille M, Muller T, Wenning GK. Patient Evaluation of a Home Diary to Assess Duration and Severity of Dyskinesia in Parkinson Disease. <u><i>Clin Neuropharmacol.</i> 2006 November/December;29(6):322-30.</u>
151	Ransmayr G, Katzenschlager R, Dal-Bianco P, Wenning G, Bancher C, Jellinger K, Schmidt R, Poewe W. [Dementia with Lewy Bodies and its differentiation from Alzheimer's disease]. <u><i>Neuropsychiatr.</i> 2007;21(2):63-74.</u>
152	Jellinger KA, Wenning GK, Seppi K. Predictors of survival in dementia with lewy bodies and Parkinson dementia. <u><i>Neurodegener Dis.</i> 2007;4(6):428-30.</u>
153	Peralta C, Stampfer-Kountchev M, Karner E, Kollensperger M, Geser F, Wolf E, Seppi K, Benke T, Poewe W, Wenning GK. Orthostatic hypotension and attention in Parkinson's disease with and without dementia. <u><i>J Neural Transm.</i> 2007;114(5):585-8.</u>

154	Kollensperger M, Stampfer-Kountchev M, Seppi K, Geser F, Frick C, Del Sorbo F, Albanese A, Gurevich T, Giladi N, Djaldetti R, Schrag A, Low PA, Mathias CJ, Poewe W, Wenning GK. Progression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment. <i>Eur J Neurol.</i> 2007 Jan;14(1):66-72.
155	Loscher WN, Stampfer-Kountchev M, Sawires M, Seppi K, Mueller J, Szubski C, Hirnsperger K, Brenneis C, Poewe W, Wenning GK. Abnormal responses to repetitive transcranial magnetic stimulation in multiple system atrophy. <i>Mov Disord.</i> 2007 Jan 15;22(2):174-8.
156	Brenneis C, Egger K, Scherfler C, Seppi K, Schocke M, Poewe W, Wenning GK. Progression of brain atrophy in multiple system atrophy : A longitudinal VBM study. <i>J Neurol.</i> 2007 Feb;254(2):191-6.
157	Kollensperger M, Stefanova N, Reindl M, Poewe W, Wenning GK. Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy. <i>Mov Disord.</i> 2007 Feb;22(3):353-8.
158	Stockner H, Sojer M, K KS, Mueller J, Wenning GK, Schmidauer C, Poewe W. Midbrain sonography in patients with essential tremor. <i>Mov Disord.</i> 2007 Feb;22(3):414-7.
159	Boesch SM, Wolf C, Seppi K, Felber S, Wenning GK, Schocke M. Differentiation of SCA2 from MSA-C using proton magnetic resonance spectroscopic imaging. <i>J Magn Reson Imaging.</i> 2007 Mar;25(3):564-9.
160	Boesch SM, Mueller J, Wenning GK, Poewe W. Cervical dystonia in spinocerebellar ataxia type 2: Clinical and polymyographic findings. <i>J Neurol Neurosurg Psychiatry.</i> 2007 May;78(5):520-2.
161	Stefanova N, Kollensperger M, Hainzer M, Cenci A, Poewe W, Wenning GK. High dose levodopa therapy is not toxic in multiple system atrophy: Experimental evidence. <i>Mov Disord.</i> 2007 May 15;22(7):969-73.
162	Holmberg B, Johansson JO, Poewe W, Wenning G, Quinn NP, Mathias C, Tolosa E, Cardozo A, Dizdar N, Rascol O, Slaoui T; Growth-Hormone MSA Study GroupMembers of the Growth-Hormone MSA Study Group and the European MSA Study Group are listed as an Appendix; European MSA Study Group (EMSA-SG). Safety and tolerability of growth hormone therapy in multiple system atrophy: A double-blind, placebo-controlled study. <i>Mov Disord.</i> 2007 Apr 27;22(8):1138-1144.
163	Hering S, Wenning GK, Seppi K, Poewe W, Mueller J. An open trial of levetiracetam for segmental and generalized dystonia. <i>Mov Disord.</i> 2007 Aug 15;22(11):1649-51.
164	Egger K, Mueller J, Schocke M, Brenneis C, Rinnerthaler M, Seppi K, Trieb T, Wenning GK, Hallett M, Poewe W. Voxel based morphometry reveals specific gray matter changes in primary dystonia. <i>Mov Disord.</i> 2007 Aug 15;22(11):1538-42.
165	Kollensperger M, Seppi K, Liener C, Boesch S, Heute D, Mair KJ, Mueller J, Sawires M, Scherfler C, Schocke MF, Donnemilier E, Virgolini I, Wenning GK, Poewe W. Diffusion weighted imaging best discriminates PD from MSA-P: A comparison with tilt table testing and heart MIBG scintigraphy. <i>Mov Disord.</i> 2007 Sep 15;22(12):1771-1776.
166	Martinez-Rodriguez JE, Seppi K, Cardozo A, Iranzo A, Stampfer-Kountchev M, Wenning G, Tolosa E, Hogg B, Santamaria J, Poewe W; SINBAR (Sleep Innsbruck Barcelona) group. Cerebrospinal fluid hypocretin-1 levels in multiple system atrophy. <i>Mov Disord.</i> 2007 Sep 15;22(12):1822-4.
167	Stefanova N, Reindl M, Neumann M, Kahle PJ, Poewe W, Wenning GK. Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: Implications for multiple system atrophy. <i>Mov Disord.</i> 2007 Nov 15;22(15):2196-203.
168	Sinz H, Zamarian L, Benke T, Wenning GK, Delazer M. Impact of ambiguity and risk on

	decision making in mild Alzheimer's disease. <u><i>Neuropsychologia</i>. 2008;46(7):2043-55.</u>
169	Schrag A, Wenning GK, Quinn N, Ben-Shlomo Y. Survival in multiple system atrophy. <u><i>Mov Disord</i>. 2008 Jan 30;23(2):294-6.</u>
170	Stefanova N, Poewe W, Wenning GK. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. <u><i>Exp Neurol</i>. 2008 Apr;210(2):421-7.</u>
171	Quinn N, Barker RA, Wenning GK. Are trials of intravascular infusions of autologous mesenchymal stem cells in patients with multiple system atrophy currently justified, and are they effective? <u><i>Clin Pharmacol Ther</i>. 2008 May;83(5):663-5.</u>
172	Köllensperger M, Geser F, Seppi K, Stampfer-Kountchev M, Sawires M, Scherfler C, Boesch S, Mueller J, Koukouni V, Quinn N, Pellecchia MT, Barone P, Schimke N, Dodel R, Oertel W, Dupont E, Østergaard K, Daniels C, Deuschl G, Gurevich T, Giladi N, Coelho M, Sampaio C, Nilsson C, Widner H, Sorbo FD, Albanese A, Cardozo A, Tolosa E, Abele M, Klockgether T, Kamm C, Gasser T, Djaldetti R, Colosimo C, Meco G, Schrag A, Poewe W, Wenning GK; European MSA Study Group. Red flags for multiple system atrophy. <u><i>Mov Disord</i>. 2008 Jun 15;23(8):1093-9.</u>
173	Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Dürr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M. Second consensus statement on the diagnosis of multiple system atrophy. <u><i>Neurology</i>. 2008 Aug 26;71(9):670-6.</u>
174	Abdo W F, Wenning GK, Bloem BR. Een diagnose in het achterhoofd. <u><i>Tijdschr Neurol Neurochirurg</i>. 2008;109(8):343-4.</u>
175	Köllensperger M, Wenning GK. Assessing disease progression with MRI in atypical parkinsonian disorders. <u><i>Mov Disord</i>. 2009;24 Suppl 2:S699-702.</u>
176	Petzold A, Thompson EJ, Keir G, Quinn N, Holmberg B, Dizdar N, Wenning GK, Rascol O, Tolosa E, Rosengren L. Longitudinal one-year study of levels and stoichiometry of neurofilament heavy and light chain concentrations in CSF in patients with multiple system atrophy. <u><i>J Neurol Sci</i>. 2009 Apr 15;279(1-2):76-9.</u>
177	Diem-Zangerl A, Seppi K, Wenning GK, Trinkla E, Ransmayr G, Oberaigner W, Poewe W. Mortality in Parkinson's disease: A 20-year follow-up study. <u><i>Mov Disord</i>. 2009 Apr 30;24(6):819-25.</u>
178	Wenning GK, Brown R. Dementia in multiple system atrophy: does it exist? <u><i>Eur J Neurol</i>. 2009 May;16(5):551-2.</u>
179	Scholz SW, Houlden H, Schulte C, Sharma M, Li A, Berg D, Melchers A, Paudel R, Gibbs JR, Simon-Sanchez J, Paisan-Ruiz C, Bras J, Ding J, Chen H, Traynor BJ, Arepalli S, Zonozi RR, Revesz T, Holton J, Wood N, Lees A, Oertel W, Wüllner U, Goldwurm S, Pellecchia MT, Illig T, Riess O, Fernandez HH, Rodriguez RL, Okun MS, Poewe W, Wenning GK, Hardy JA, Singleton AB, Gasser T. SNCA variants are associated with increased risk for multiple system atrophy. <u><i>Ann Neurol</i>. 2009 May;65(5):610-4.</u>
180	Köllensperger M, Stefanova N, Pallua A, Puschban Z, Dechant G, Hainzer M, Reindl M, Poewe W, Nikkhah G, Wenning GK. Striatal transplantation in a rodent model of multiple system atrophy: Effects on L-Dopa response. <u><i>J Neurosci Res</i>. 2009 May 15;87(7):1679-85.</u>
181	Lipp A, Sandroni P, Ahlskog JE, Fealey RD, Kimpinski K, Iodice V, Gehrking TL, Weigand SD, Sletten DM, Gehrking JA, Nickander KK, Singer W, Maraganore DM, Gilman S, Wenning GK, Shults CW, Low PA. Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure. <u><i>Arch Neurol</i>. 2009 Jun;66(6):742-50.</u>
182	Delazer M, Sinz H, Zamarian L, Stockner H, Seppi K, Wenning GK, Benke T, Poewe W. Decision making under risk and under ambiguity in Parkinson's disease.

	<u><i>Neuropsychologia</i>. 2009 Jul;47(8-9):1901-8.</u>
183	Lim SY, Wadia P, Wenning GK, Lang AE. Clinically probable multiple system atrophy with predominant parkinsonism associated with myotonic dystrophy type 2. <u><i>Mov Disord</i>. 2009 Jul 15;24(9):1407-9.</u>
184	Ubhi K, Lee PH, Adame A, Inglis C, Mante M, Rockenstein E, Stefanova N, Wenning GK, Masliah E. Mitochondrial inhibitor 3-nitropropionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy. <u><i>J Neurosci Res</i>. 2009 Sep;87(12):2728-39.</u>
185	Stefanova N, Hainzer M, Stemberger S, Couillard-Després S, Aigner L, Poewe W, Wenning GK. Striatal transplantation for multiple system atrophy--are grafts affected by alpha-synucleinopathy? <u><i>Exp Neurol</i>. 2009 Sep;219(1):368-71.</u>
186	Tiefenthaler W, Wenning GK, Gruber H, Benzer A. Sonographic diagnosis of catheter malposition in a patient with postoperative plexus lesion after right internal jugular vein catheterization--case report. <u><i>Middle East J Anesthesiol</i>. 2009 Oct;20(3):443-5.</u>
187	Peralta CM, Frauscher B, Seppi K, Wolf E, Wenning GK, Högl B, Poewe W. Restless legs syndrome in Parkinson's disease. <u><i>Mov Disord</i>. 2009 Oct 30;24(14):2076-80.</u>
188	Loscher WN, Wenning GK. No need to droop your head in Parkinson's disease? <u><i>Parkinsonism Relat Disord</i>. 2009 Nov;15(9):620.</u>
189	Osaki Y, Ben-Shlomo Y, Lees AJ, Wenning GK, Quinn NP. A validation exercise on the new consensus criteria for multiple system atrophy. <u><i>Mov Disord</i>. 2009 Nov 15;24(15):2272-6.</u>
190	Finke C, Siebert E, Plotkin M, Wenning GK, Reuter U. Multiple system atrophy masking multiple sclerosis. <u><i>Clin Neurol Neurosurg</i>. 2010 Jan;112(1):59-61.</u>
191	Dodel R, Spottke A, Gerhard A, Reuss A, Reinecker S, Schimke N, Trenkwalder C, Sixel-Döring F, Herting B, Kamm C, Gasser T, Sawires M, Geser F, Köllensperger M, Seppi K, Kloss M, Krause M, Daniels C, Deuschl G, Böttger S, Naumann M, Lipp A, Gruber D, Kupsch A, Du Y, Turkheimer F, Brooks DJ, Klockgether T, Poewe W, Wenning G, Schade-Brittinger C, Oertel WH, Eggert K. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). <u><i>Mov Disord</i>. 2010 Jan 15;25(1):97-107.</u>
192	Schunk E, Aigner C, Stefanova N, Wenning G, Herzog H, Schwarzer C. Kappa opioid receptor activation blocks progressive neurodegeneration after kainic acid injection. <u><i>Hippocampus</i>. 2010 Jun 1. doi: 10.1002/hipo.20813. [Epub ahead of print]</u>
193	Dürr S, Wenning GK. Autonomes Versagen bei Parkinsonsyndromen. <u><i>Jatros Neurologie &amp; Psychiatrie</i>. 2010 Mai;18(3):20-2.</u>
194	Stemberger S, Poewe W, Wenning GK, Stefanova N. Targeted overexpression of human alpha-synuclein in oligodendroglia induces lesions linked to MSA-like progressive autonomic failure. <u><i>Exp Neurol</i>. 2010 Aug;224(2):459-64.</u>
195	Geser F, Malunda JA, Hurtig HI, Duda JE, Wenning GK, Gilman S, Low PA, Lee VM, Trojanowski JQ. Subcortical TDP-43 pathology occurs infrequently in multiple system atrophy. <u><i>Neuropathol Appl Neurobiol</i>. 2010 Oct 13. doi: 10.1111/j.1365-2990.2010.01136.x.</u>
196	Köllensperger M, Geser F, Ndayisaba JP, Boesch S, Seppi K, Ostergaard K, Dupont E, Cardozo A, Tolosa E, Abele M, Klockgether T, Yekhlef F, Tison F, Daniels C, Deuschl G, Coelho M, Sampaio C, Bozi M, Quinn N, Schrag A, Mathias CJ, Fowler C, Nilsson CF, Widner H, Schimke N, Oertel W, Del Sorbo F, Albanese A, Pellecchia MT, Barone P, Djaldetti R, Colosimo C, Meo G, Gonzalez-Mandly A, Berciano J, Gurevich T, Giladi N, Galitzky M, Rascol O, Kamm C, Gasser T, Siebert U, Poewe W, Wenning GK; EMSA-SG. Presentation, diagnosis, and management of multiple system atrophy in Europe: final

	analysis of the European multiple system atrophy registry. <i>Mov Disord.</i> 2010 Nov 15;25(15):2604-12.
197	Moreno-López C, Santamaría J, Salamero M, Del Sorbo F, Albanese A, Pellecchia MT, Barone P, Overeem S, Bloem B, Aarden W, Canesi M, Antonini A, Duerr S, Wenning GK, Poewe W, Rubino A, Meco G, Schneider SA, Bhatia KP, Djaldetti R, Coelho M, Sampaio C, Cochen V, Hellriegel H, Deuschl G, Colosimo C, Marsili L, Gasser T, Tolosa E. Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study). <i>Arch Neurol.</i> 2011 Feb;68(2):223-30.
198	Stemberger S, Jamnig A, Stefanova N, Lepperdinger G, Reindl M, Wenning GK. Mesenchymal stem cells in a transgenic mouse model of multiple system atrophy: immunomodulation and neuroprotection. <i>PLoS One.</i> 2011;6(5):e19808.
199	Köllensperger M, Krismer F, Pallua A, Stefanova N, Poewe W, Wenning GK. Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy. <i>Mov Disord.</i> 2011 Jan 6.
200	Moreno-López C, Santamaría J, Salamero M, Del Sorbo F, Albanese A, Pellecchia MT, Barone P, Overeem S, Bloem B, Aarden W, Canesi M, Antonini A, Duerr S, Wenning GK, Poewe W, Rubino A, Meco G, Schneider SA, Bhatia KP, Djaldetti R, Coelho M, Sampaio C, Cochen V, Hellriegel H, Deuschl G, Colosimo C, Marsili L, Gasser T, Tolosa E. Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study). <i>Arch Neurol.</i> 2011 Feb;68(2):223-30.
201	Köllensperger M, Krismer F, Pallua A, Stefanova N, Poewe W, Wenning GK. Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy. <i>Mov Disord.</i> 2011 Feb 15;26(3):507-15.
202	Goebel G, Seppi K, Donnemiller E, Warwitz B, Wenning GK, Virgolini I, Poewe W, Scherfler C. A novel computer-assisted image analysis of [123I]β-CIT SPECT images improves the diagnostic accuracy of parkinsonian disorders. <i>Eur J Nucl Med Mol Imaging.</i> 2011 Apr;38(4):702-10.
203	Wenning GK, Litvan I, Tolosa E. Milestones in atypical and secondary Parkinsonisms. <i>Mov Disord.</i> 2011 May;26(6):1083-95.
204	Stemberger S, Wenning GK. Modelling progressive autonomic failure in MSA: where are we now? <i>J Neural Transm.</i> 2011 May;118(5):841-7.
205	Geser F, Malunda JA, Hurtig HI, Duda JE, Wenning GK, Gilman S, Low PA, Lee VM, Trojanowski JQ. TDP-43 pathology occurs infrequently in multiple system atrophy. <i>Neuropathol Appl Neurobiol.</i> 2011 Jun;37(4):358-65.
206	Fellner L, Jellinger KA, Wenning GK, Stefanova N. Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts. <i>Acta Neuropathol.</i> 2011 Jun;121(6):675-93.
207	Höglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, van Swieten JC, Heutink P, Wszolek ZK, Uitti RJ, Vandrovцова J, Hurtig HI, Gross RG, Maetzler W, Goldwurm S, Tolosa E, Borroni B, Pastor P; PSP Genetics Study Group, Cantwell LB, Han MR, Dillman A, van der Brug MP, Gibbs JR, Cookson MR, Hernandez DG, Singleton AB, Farrer MJ, Yu CE, Golbe LI, Revesz T, Hardy J, Lees AJ, Devlin B, Hakonarson H, Müller U, Schellenberg GD. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. <i>Nat Genet.</i> 2011 Jun 19;43(7):699-705.
208	Stefanova N, Fellner L, Reindl M, Masliah E, Poewe W, Wenning GK. Toll-like receptor 4 promotes α-synuclein clearance and survival of nigral dopaminergic neurons. <i>Am J Pathol.</i> 2011 Aug;179(2):954-63.
209	Wenning GK, Granata R, Krismer F, Dürr S, Seppi K, Poewe W, Bleasdale-Barr K,

	Mathias CJ. Orthostatic Hypotension Is Differentially Associated with the Cerebellar Versus the Parkinsonian Variant of Multiple System Atrophy: a Comparative Study. <i>Cerebellum</i> . 2011 Aug 6.
210	Pavy-Le Traon A, Amarenco G, Duerr S, Kaufmann H, Lahrmann H, Shaftman SR, Tison F, Wenning GK, Goetz CG, Poewe W, Sampaio C, Schrag A, Stebbins GT, Rascol O. The Movement Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension. <i>Mov Disord</i> . 2011 Sep;26(11):1985-92.
211	Stemberger S, Scholz SW, Singleton AB, Wenning GK. Genetic players in multiple system atrophy: unfolding the nature of the beast. <i>Neurobiol Aging</i> . 2011 Oct;32(10):1924.e5-14.
212	Saft C, Eppelen JT, Wieczorek S, Landwehrmeyer GB, Roos RA, de Yebenes JG, Dose M, Tabrizi SJ, Craufurd D; REGISTRY Investigators of the European Huntington's Disease Network, Arning L. NMDA receptor gene variations as modifiers in Huntington disease: a replication study. <i>PLoS Curr</i> . 2011 Oct 4;3:RRN1247.
213	Frauscher B, Nomura T, Duerr S, Ehrmann L, Gschliesser V, Wenning GK, Wolf E, Inoue Y, Högl B, Poewe W. Investigation of autonomic function in idiopathic REM sleep behavior disorder. <i>J Neurol</i> . 2011 Nov 8.
214	Onofrij M, Thomas A, Tiraboschi P, Wenning G, Gambi F, Sepede G, Di Giannantonio M, Di Carmine C, Monaco D, Maruotti V, Ciccocioppo F, D'Amico MC, Bonanni L. Updates on Somatoform Disorders (SFMD) in Parkinson's Disease and Dementia with Lewy Bodies and discussion of phenomenology. <i>J Neurol Sci</i> . 2011 Nov 15;310(1-2):166-71.
215	Orth M; European Huntington's Disease Network, Handley OJ, Schwenke C, Dunnett S, Wild EJ, Tabrizi SJ, Landwehrmeyer GB. Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY. <i>J Neurol Neurosurg Psychiatry</i> . 2011 Dec;82(12):1409-12.
216	Quarrell OW, Handley O, O'Donovan K, Dumoulin C, Ramos-Arroyo M, Biunno I, Bauer P, Kline M, Landwehrmeyer GB; European Huntington's Disease Network. Discrepancies in reporting the CAG repeat lengths for Huntington's disease. <i>Eur J Hum Genet</i> . 2012 Jan;20(1):20-6.
217	Jecmenica-Lukic M, Poewe W, Tolosa E, Wenning GK. Premotor signs and symptoms of multiple system atrophy. <i>Lancet Neurol</i> . 2012 Apr;11(4):361-368.
218	Stefanova N, Georgievska B, Eriksson H, Poewe W, Wenning GK. Myeloperoxidase Inhibition Ameliorates Multiple System Atrophy-Like Degeneration in a Transgenic Mouse Model. <i>Neurotox Res</i> . 2012 May;21(4):393-404.
<b>Reviews, Case Reports</b>	
1	Quinn N, Wenning G. Multiple system atrophy. Multiple system atrophy. <i>Br J Hosp Med</i> . 1994 May;51(9):492-4.
2	Tison F, Wenning GK, Daniel SE, Quinn NP. [Multiple system atrophy with Lewy bodies] <i>Rev Neurol (Paris)</i> . 1995 Jun-Jul;151(6-7):398-403.
3	Quinn NP, Wenning GK, Marsden CD. The Shy-Drager syndrome. What did Shy and Drager really describe? <i>Arch Neurol</i> . 1995 Jul;52(7):656-7.
4	Quinn N, Wenning G. Multiple system atrophy. <i>Curr Opin Neurol</i> . 1995 Aug;8(4):323-6.
5	Wenning GK, Quinn NP, Daniel SE, Garratt H, Marsden CD. Facial dystonia in pathologically proven multiple system atrophy: a video report. <i>Mov Disord</i> . 1996 Jan;11(1):107-9.
6	Quinn NP, Wenning GK. Multiple system atrophy. <i>Adv Neurol</i> . 1996;69:413-9.

7	Poewe WH, Wenning GK. The natural history of Parkinson's disease. <u><i>Neurology</i>. 1996 Dec;47(6 Suppl 3):S146-152.</u>
8	Litvan I, Agid Y, Goetz C, Jankovic J, Wenning GK, Brandell JP, Lai EC, Verny M, Ray-Chaudhuri K, McKee A, Jellinger K, Pearce RK, Bartko JJ. Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. <u><i>Neurology</i>. 1997 Jan;48(1):119-25.</u>
9	Wenning GK, Pramstaller PP, Ransmayr G, Poewe W. Atypical Parkinson syndrome. <u><i>Nervenarzt</i>. 1997 Feb;68(2):102-15.</u>
10	Wenning GK, Quinn NP. Parkinsonism. Multiple system atrophy. <u><i>Baillieres Clin Neurol</i>. 1997 Apr;6(1):187-204.</u>
11	Wenning GK, Granata R. Multiple system atrophy: more on the nature of the beast. <u><i>Neurologia</i>. 1998 Mar;13(3):105-10.</u>
12	Kofler M, Wenning GK, Poewe W. Cortical and brain stem hyperexcitability in striatonigral degeneration. <u><i>Mov Disord</i>. 1998 May;13(3):602-7.</u>
13	Poewe W, Wenning GK. The natural history of Parkinson's disease. <u><i>Ann Neurol</i>. 1998 Sep;44(3 Suppl 1):S1-9.</u>
14	Gilman S, Low P, Quinn N, Albanese A, Ben-Shlomo Y, Fowler C, Kaufmann H, Klockgether T, Lang A, Lantos P, Litvan I, Mathias C, Oliver E, Robertson D, Schatz I, Wenning G. Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. <u><i>Clin Auton Res</i>. 1998 Dec;8(6):359-62.</u>
15	Gilman S, Low PA, Quinn NP, Albanese A, Ben-Shlomo Y, Fowler CJ, Kaufmann H, Klockgether T, Lang AE, Lantos PL, Litvan I, Mathias CJ, Oliver E, Robertson D, Schatz I, Wenning GK. Consensus statement on the diagnosis of multiple system atrophy. <u><i>J Auton Nerv Syst</i>. 1998 Dec;74(2-3):189-92.</u>
16	Wenning GK, Granata R, Puschban Z, Scherfler C, Poewe W. Neural transplantation in animal models of multiple system atrophy: a review. <u><i>J Neural Transm Suppl</i>. 1999;55:103-13.</u>
17	Wenning GK, Bosch S, Luginger E, Wagner M, Poewe W. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease. <u><i>Adv Neurol</i>. 1999;80:545-8.</u>
18	Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, Kaufmann H, Klockgether T, Lang AE, Lantos PL, Litvan I, Mathias CJ, Oliver E, Robertson D, Schatz I, Wenning GK. Consensus statement on the diagnosis of multiple system atrophy. <u><i>J Neurol Sci</i>. 1999 Feb;163(1):94-8.</u>
19	Wenning GK, Luginger E, Sailer U, Poewe W, Donnemiller E, Riccabona G. Postoperative parkinsonian tremor in a patient with a frontal meningioma. <u><i>Mov Disord</i>. 1999 Mar;14(2):366-8.</u>
20	Gilman S, Low P, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, Kaufmann H, Klockgether T, Lang A, Lantos P, Litvan I, Mathias C, Oliver E, Robertson D, Schatz I, Wenning GK. [Consensus on the diagnosis of multi-system atrophy] <u><i>Neurologia</i>. 1999 Nov;14(9):425-8.</u>
21	Stefanova N, Seppi K, Scherfler C, Puschban Z, Wenning GK. Depression in alpha-synucleinopathies: prevalence, pathophysiology and treatment. <u><i>J Neural Transm Suppl</i>. 2000;(60):335-43.</u>
22	Kofler M, Wenning GK, Poewe W, Jellinger K, Maier H. Cortical and brain stem hyperexcitability in a pathologically confirmed case of multiple system atrophy. <u><i>Mov Disord</i>. 2000 Mar;15(2):362-3.</u>
23	Wenning GK, Tison F, Scherfler C, Puschban Z, Waldner R, Granata R, Ghorayeb I,



	Poewe W. Towards neurotransplantation in multiple system atrophy: clinical rationale, pathophysiological basis, and preliminary experimental evidence. <i>Cell Transplant. 2000 Mar-Apr;9(2):279-88.</i>
24	Poewe W, Wenning GK. Apomorphine: an underutilized therapy for Parkinson's disease. <i>Mov Disord. 2000 Sep;15(5):789-94.</i>
25	Ransmayr G, Wenning GK, Seppi K, Jellinger K, Poewe W. Dementia with Lewy bodies <i>Nervenarzt. 2000 Dec;71(12):929-35.</i>
26	Wenning GK, Seppi K, Scherfler C, Stefanova N, Puschban Z. Multiple system atrophy. <i>Semin Neurol. 2001;21(1):33-40.</i>
27	Wenning GK; Braune S. Multiple system atrophy: pathophysiology and management. <i>CNS Drugs. 2001;15(11):839-52.</i>
28	Müller J, Wenning GK, Wissel J, Poewe W. Intrafamilial heterogeneity of facial hyperkinesias: chance association of tics, cranial dystonia, and Huntington's disease? <i>Mov Disord. 2001 Mar;16(2):370-2.</i>
29	Marras C, Lang AE, Ang LC, Zijlmans JCM, Wenning GK. Clinical Grand Rounds. 69-year-old man with gait disturbance and Parkinsonism. <i>Mov Disord. 2001 May;16(3):548-61.</i>
30	Wenning GK, Seppi K. [Diagnosis and therapy of multiple system atrophy]. <i>Schweiz Rundsch Med Prax. 2001 Jun;90(23):1035-40.</i>
31	Poewe W, Wenning G. The differential diagnosis of Parkinson's disease. <i>Eur J Neurol. 2002 Nov;9(Suppl 3):23-30.</i>
32	Wenning GK, Geser F. Multiple system atrophy. <i>Rev Neurol (Paris). 2003 May;159(5 Pt 2):3531-8.</i>
33	Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. <i>Lancet Neurol. 2004 Feb;3(2):93-103. Erratum in: Lancet Neurol. 2004 Mar;3(3):137.</i>
34	Bonelli RM, Wenning GK, Kapfhammer HP. Huntington's disease: present treatments and future therapeutic modalities. <i>Int Clin Psychopharmacol. 2004 Mar;19(2):51-62.</i>
35	Wenning GK, Jellinger K. The role of alpha-synuclein in the pathogenesis of multiple system atrophy. <i>Acta Neuropathol (Berl). 2005 Feb;109(2):129-40.</i>
36	Geser F, Wenning GK. Clinical presentation and management of multiple system atrophy and progressive supranuclear palsy. <i>Psychopharmako-therapie. 2005;12(2):40-50.</i>
37	Geser F, Wenning GK, Poewe W, McKeith I. How to diagnose dementia with Lewy bodies: state of the art. <i>Mov Disord. 2005 Aug;20(Suppl 12):S11-20.</i>
38	Wenning GK, Jellinger K. The role of alpha-synuclein and tau in neurodegenerative movement disorders. <i>Curr Opin Neurol. 2005 Aug;18(4):357-62.</i>
39	Stefanova N, Tison F, Reindl M, Poewe W, Wenning GK. Animal models of multiple system atrophy. <i>Trends Neurosci. 2005 Sep;28(9):501-6.</i>
40	Seppi K, Schocke MF, Wenning GK, Poewe W. How to diagnose MSA early: the role of magnetic resonance imaging. <i>J Neural Transm. 2005 Dec;112(12):1625-34.</i>
41	Geser F, Seppi K, Stampfer-Kountchev M, Kollensperger M, Diem A, Ndayisaba JP, Ostergaard K, Dupont E, Cardozo A, Tolosa E, Abele M, Dodel R, Klockgether T, Ghorayeb I, Yekhlief F, Tison F, Daniels C, Kopper F, Deuschl G, Coelho M, Ferreira J, Rosa MM, Sampaio C, Bozi M, Schrag A, Hooker J, Kim H, Scaravilli T, Mathias CJ, Fowler C, Wood N, Quinn N, Widner H, Nilsson CF, Lindvall O, Schimke N, Eggert KM, Oertel W, del Sorbo F, Carella F, Albanese A, Pellecchia MT, Barone P, Djaldetti R, Meco G, Colosimo C, Gonzalez-Mandly A, Berciano J, Gurevich T, Giladi N, Galitzky M, Ory F, Rascol O, Kamm C, Buerk K, Maass S, Gasser T, Poewe W, Wenning GK; EMSA-SG. The European Multiple System Atrophy-Study Group (EMSA-SG). <i>J Neural Transm. 2005 Dec;112(12):1677-86.</i>

42	Colosimo C, Tiple D, Wenning GK. Management of multiple system atrophy: state of the art. <i>J Neural Transm.</i> 2005 Dec;112(12):1695-704.
43	Tolosa E, Wenning GK, Poewe W. The diagnosis of Parkinson's disease. <i>Lancet Neurol.</i> 2006 Jan;5(1):75-86.
44	Bonelli RM, Wenning GK. Pharmacological management of Huntington's disease: an evidence-based review. <i>Curr Pharm Des.</i> 2006;12(21):2701-20.
45	Cardoso F, Seppi K, Mair KJ, Wenning GK, Poewe W. Seminar on choreas. <i>Lancet Neurol.</i> 2006 Jul;5(7):589-602.
46	Berciano J, Boesch S, Perez-Ramos JM, Wenning GK. Olivopontocerebellar atrophy: toward a better nosological definition. <i>Mov Disord.</i> 2006 Oct;21(10):1607-13.
47	Ransmayr G, Katzenschlager R, Dal-Bianco P, Wenning G, Bancher C, Jellinger K, Schmidt R, Poewe W. Dementia with Lewy Bodies and its differentiation from Alzheimer's disease. <i>Neuropsychiatr.</i> 2007;21(2):63-74.
48	Gilman S., Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood N., Colosimo C., Durr A., Fowler CJ, Kaufmann H., Klockgether T., Lees AJ, Poewe W., Quinn NP, Revesz T., Robertson D., Sandroni P., Seppi K., Vidailhet M. Second consensus statement on the diagnosis of multiple system atrophy. <i>Neurology.</i> 2008 Aug 26;71(9):670-6.
49	Geser F., Egger KE, Wenning GK. A face to remember. <i>Mov Disord.</i> 2008 [in press]
50	Wenning GK, Stefanova N, Jellinger KA, Poewe W, Schlossmacher MG. Multiple system atrophy: a primary oligodendroglipathy. <i>Ann Neurol.</i> 2008 Sep;64(3):239-46.
51	Wenning GK, Stefanova N. Recent developments in multiple system atrophy. <i>J Neurol.</i> 2009 Nov;256(11):1791-808.
52	Stefanova N, Bücke P, Duerr S, Wenning GK. Multiple system atrophy: an update. <i>Lancet Neurol.</i> 2009 Dec;8(12):1172-8.
53	Wenning GK, Colosimo C. Diagnostic criteria for multiple system atrophy and progressive supranuclear palsy. <i>Rev Neurol (Paris).</i> 2010 Oct;166(10):829-33.
54	Wenning GK, Krismer F, Poewe W. New insights into atypical parkinsonism. <i>Curr Opin Neurol.</i> 2011 Aug;24(4):331-8.
<b>Letters to the Editor, Editorials, Comments</b>	
1	Wenning GK, Quinn NP, Daniel SE. How accurate is death certification of multiple system atrophy? <i>Lancet.</i> 1992 Dec;340(8833):1481-2.
2	Wenning GK, Wagner S, Daniel S, Quinn NP. Multiple system atrophy: sporadic or familial? <i>Lancet.</i> 1993 Sep;342(8872):681.
3	Davie CA, Wenning GK, Barker GJ, Brennan A, Quinn N, Miller MD. MRS to differentiate multiple system atrophy from idiopathic Parkinson's disease. <i>Lancet.</i> 1993 Sep;342(8872):681-2.
4	Wenning G, Quinn N. Are Lewy bodies non-specific epiphenomena of nigral damage? <i>Mov Disord.</i> 1994 May;9(3):378-9.
5	Ben-Shlomo Y, Wenning G. Incidental Lewy body disease. <i>Lancet.</i> 1994 Nov;344(8935):1503.
6	Tison F, Wenning GK, Quinn NP, Smith SJ. REM sleep behaviour disorder as the presenting symptom of multiple system atrophy. <i>J Neurol Neurosurg Psychiatry.</i> 1995 Mar;58(3):379-80.
7	Bandmann O, Wenning GK, Quinn NP, Harding AE. Arg296 to Cys296 polymorphism in exon 6 of cytochrome P-450-2D6 (CYP2D6) is not associated with multiple system atrophy. <i>J Neurol Neurosurg Psychiatry.</i> 1995 Nov;59(5):557.

8	Litvan, I, McKee A, Jellinger K, Jankovic J, Wenning GK; for the PSP Study Group. What are the Obstacles for an Accurate Clinical Diagnosis of Pick's disease? <u><i>Neurology</i>. 1998 Apr;50(4):1192-1193.</u>
9	Jellinger KA, Wenning GK. An early description of striatonigral degeneration. <u><i>J Neurol</i>. 2000 Apr;247(4):309-12.</u>
10	Seppi K, Puschban Z, Stefanova N, Scherfler C, Mueller J, Poewe W, Wenning GK. Overstimulation of the alpha1B-adrenergic receptor causes a "seizure plus" syndrome. <u><i>Nat Med</i>. 2001 Feb;7(2):132.</u>
11	Wenning GK, Diem A. Is peripheral neuropathy a feature of multiple system atrophy? <u><i>Clin Auton Res</i>. 2001 Apr;11(2):63.</u>
12	Bauer I, Gencik M, Laccone F, Peters H, Weber BH, Feder EH, Weirich H, Morris-Rosendahl DJ, Rolfs A, Gencikova A, Bauer P, Wenning GK, Epplen JT, Holmes SE, Margolis RL, Ross CA, Riess O. Trinucleotide repeat expansions in the junctophilin-3 gene are not found in Caucasian patients with a Huntington's disease-like phenotype. <u><i>Ann Neurol</i>. 2002 May;51(5):662.</u>
13	Jellinger KA, Seppi K, Wenning GK. Lewy bodies in patients presenting clinically with Alzheimer disease. <u><i>J Alzheimers Dis</i>. 2002 Aug;4(4):327-8.</u>
14	Jellinger KA, Seppi K, Wenning GK. Accuracy of diagnosis in dementia with Lewy bodies. <u><i>Arch Neurol</i>. 2003 Mar;60(3):452.</u>
15	Jellinger KA, Seppi K, Wenning GK. Neuropathologic changes in Parkinson disease with late onset of dementia. <u><i>Arch Neurol</i>. 2003 Mar;60(3):452-3; author reply 453-4.</u>
16	Jellinger KA, Seppi K, Wenning GK. Clinical and neuropathological correlates of Lewy body disease. <u><i>Acta Neuropathol (Berl)</i>. 2003 Aug;106(2):188-9; author reply 190.</u>
17	Wenning GK, Geser F, Poewe W. The 'risus sardonius' of multiple system atrophy. <u><i>Mov Disord</i>. 2003 Oct;18(10):1211.</u>
18	Diguet E, Gross CE, Bezard E, Tison F, Stefanova N, Wenning GK. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. <u><i>Neurology</i>. 2004 Jan;62(1):158; author reply 158-9.</u>
19	Mueller J, Wenning GK, Poewe W, Kemmler G. Re: Patient-based outcomes of cervical dystonia: a review of rating scales. <u><i>Mov Disord</i>. 2005 Sep;20(9):1230.</u>
20	Geser F, Wenning GK. Disproportionate antecollis: a warning sign for multiple system atrophy. <u><i>Mov Disord</i>. 2007 Oct 15;22(13):1986; author reply 1986-7.</u>
21	Mizuno Y, Wenning GK. Preface. <u><i>Mov Disord</i>. 2007 Dec 14;22(S17):S325-S326.</u>
<b>Books and Book Chapters</b>	
1	Wenning GK, Quinn NP. Multiple system atrophy: recent advances in clinical and pathological definition. In: Harkness W, Hayward RD, Meierkord H, Quinn NP, Scadding JW, Shorvon SD, Wade JPH (eds.). Peer selected citations `93. Neurology and Neurosurgery. <u><i>Current Medical Literature Ltd, 1993, London, pp 60-3.</i></u>
2	Wenning GK, Quinn NP. Multiple system atrophy. In : Quinn NP (ed.). Bailliere's Clinical Neurology. Parkinsonism. <u><i>Bailliere Tindall, 1997, London, pp 187-204.</i></u>
3	Poewe W, Wenning GK. Chorea and ballism. In: Tolosa E, Koller WC, Gershanik OS (eds.). Differential diagnosis and treatment of movement disorders. <u><i>Butterworth-Heinemann, 1998, Boston, pp 77-88.</i></u>
4	Poewe W, Wenning GK. Levodopa in Parkinson's disease: mechanisms of action and pathophysiology of late failure. In: Jankovic J, Tolosa E (eds.). Parkinson's disease and movement disorders. <u><i>Lippincott / Williams &amp; Wilkins, 1998, Philadelphia, pp 177-90.</i></u>
5	Poewe W, Wenning GK, Gerlach M, Riederer P. Nicht-idiopathische Parkinson-

	Syndrome. In: Hopf HC, Deuschl G, Diener HC, Reichmann H (Hrsg.). Neurologie in Praxis und Klinik. Band II. 3. Auflage. <u>Thieme, 1999, Stuttgart, pp 69-78.</u>
6	Wenning GK, Bösch S, Luginer E, Wagner M, Poewe W. Effects of Long-term, Continuous Subcutaneous Apomorphine Infusions on Motor Complications in Advanced Parkinson's Disease. In: Stern GM (ed.). Advances in Neurology. Parkinson's Disease. <u>Lippincott / Williams &amp; Wilkins, 1999, Philadelphia, pp 545-8.</u>
7	Wenning GK, Poewe W. Exkurs: Progressive supranukleäre Blickparese. In: Riederer P., Laux G., Pödlinger W (Hrsg.). Neuro-Psychopharmaka. Ein Therapiehandbuch, Band 5, 2. Auflage. <u>Springer, 1999, Wien, pp 410-5.</u>
8	Wenning GK, Poewe W. Exkurs: Multisystematrophie. In: Riederer P., Laux G., Pödlinger W (Hrsg.). Neuro-Psychopharmaka. Ein Therapiehandbuch, Band 5, 2. Auflage. <u>Springer, 1999, Wien, pp 416-21.</u>
9	Poewe W, Wenning GK. Nuevos agonistas dopaminérgicos. Es alguno realmente diferente? In: M Merello, A Lees (eds.), Tratamiento de la enfermedad de Parkinson. <u>1999, pp. 125-147.</u>
10	Poewe W, Wenning GK. Sicher therapieren mit Parkinsonmitteln, 2.Auflage. <u>pm-Verlag, 2000, Kössen.</u>
11	Scherfler C, Seppi K, Puschban Z, Weiler B, Granbichler H, Poewe W, Wenning GK. Nigral Degeneration in animal models of multiple system atrophy. In: Storch A, Collins MA (Hrsg.). Neurotoxic Factors in Parkinson's Disease and Related Disorders. <u>Kluwer Academic/Plenum Publishers, 2000, New York, pp 65-8.</u>
12	Poewe W, Wenning GK. The natural history of Parkinson's disease. In: <u>Wells Medical Ltd., 2001, Tunbridge Wells.</u>
13	Poewe W, Wenning GK. Levodopa in Parkinson's disease: mechanisms of action and pathophysiology of late failure. In: Jankovic J, Tolosa E (eds). Parkinson's disease and movement disorders, 4 <sup>th</sup> ed. <u>Lippincott/Williams &amp; Wilkins, 2002, Philadelphia, pp 104-15.</u>
14	Poewe W, Wenning GK. Morbus Parkinson. <u>Arcis, 2002, München.</u>
15	Poewe W, Wenning GK. Morbus Parkinson, Teil 2 "Spätphase". In: Conrad B, Ceballos-Baumann A (eds). Bewegungsstörungen in der Neurologie. Richtig erkennen und behandeln. <u>Thieme, 2002, Stuttgart.</u>
16	Wenning GK, Seppi K, Jellinger K. Diagnostic Accuracy in Lewy Body Dementia. In: Tolosa E, Schulz JB, McKeith IG, Ferrer I (eds.). Neurodegenerative Disorders Associated with $\alpha$ -Synuclein Pathology. <u>Alex S.A., 2002, Barcelona, pp 111-6.</u>
17	Poewe W, Wenning GK. Atypische Parkinson-Syndrome. In: Brandt T, Dichgans J, Diener C (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen, 4. Auflage. <u>Kohlhammer, 2003, Stuttgart.</u>
18	Poewe W, Wenning GK. Atypical parkinsonism. In: Brandt T, Caplan LR, Dichgans J, Diener HC, Kennard C (eds.). Neurological Disorders. Course and Treatment, 2 <sup>nd</sup> ed. <u>Elsevier Science, 2003, USA, pp 1081-98.</u>
19	Wenning GK, Stampfer M. Dementia with Lewy bodies. In: Robertson D, Biaggioni I, Burnstock G, Low PA (eds.). Primer on the Autonomic Nervous System, 2 <sup>nd</sup> ed. <u>Elsevier, 2004, San Diego, pp 293-4.</u>
20	Wenning GK, Poewe W. Where are we after 30 years of clinical experience with L-Dopa ? <u>Book/Supplement Hoffmann-La Roche, Excerpta medica, 2004, Basel.</u>
21	Rosenow F, Werhahn KJ, Wenning GK. Myoklonien. In: Sitzer M, von Stuckrad-Barre S, Schmutzhard E (Hrsg.). Neurologische Notfall- und Intensivmedizin. <u>Urban &amp; Fischer, 2004, München, pp 154-9.</u>
22	Wenning GK, Geser F, Poewe W. Multiple System Atrophy. In: Galvez-Jimenez N (ed.).

	Scientific Basis for the Treatment of Parkinson's Disease. <u>Taylor &amp; Francis, 2005, Abingdon, pp 291-8.</u>
23	Geser F, Wenning GK. Multiple System Atrophy. In: Litvan I (ed.). Atypical Parkinsonian Disorders. Clinical And Research Aspects. <u>Humana Press, 2005, Totowa, pp 335-60.</u>
24	Geser F, Colosimo C, Wenning GK. Multiple system atrophy. In: Beal MF, Lang AE, Ludolph A (eds.). Neurodegenerative Diseases. Neurobiology, Pathogenesis and Therapeutics. <u>Cambridge University Press, 2005, Cambridge, pp 623-62.</u>
25	Ghorayeb I, Stefanova N, Fernagut PO, Wenning GK, Tison F. Double-lesion animal models of multiple system atrophy. In: Le-Doux M (ed.). Animal models of movement disorders. <u>Elsevier, 2005, Amsterdam, pp 571-83.</u>
26	Wenning GK, Geser F, Poewe W. Diagnosis and treatment of multiple system atrophy: an update. In: Galvez-Jimenez N (ed.). Scientific Basis for the Treatment of Parkinson's Disease, 2 <sup>nd</sup> ed. <u>Taylor &amp; Francis, 2005, Abingdon, pp 291-8.</u>
27	Wenning GK, Geser F. Multiple system atrophy. In: Jankovic J, Tolosa E (eds.). Parkinson's disease and movement disorders, 5 <sup>th</sup> ed. <u>Lippincott / Williams and Wilkins, 2005, Baltimore, pp 175-85.</u>
28	Poewe W, Wenning GK. Klinik und Therapie des fortgeschrittenen idiopathischen Parkinson-Syndroms. In: Ceballos-Baumann A, Conrad B (Hrsg). Bewegungsstörungen, 2. überarbeitete und erweiterte Auflage. <u>Thieme, 2005, Stuttgart, pp 71-85.</u>
29	Geser F, Wenning G. Primary autonomic failure. In: Schapira AHV (ed.). Neurology: Basic and Clinical Neurosciences. <u>Elsevier, 2006, Philadelphia, pp 372-93.</u>
30	Colosimo C, Geser F, Wenning GK. Multiple system atrophy. In: Gilman S. (ed.). Neurobiology of disease. <u>Elsevier, 2007, San Diego, pp 83-93.</u>
31	Stefanova N, Granata R, Wenning GK. Morbus Parkinson und andere extrapyramidale Bewegungsstörungen. In: Berger T, Luef G, Brezinka C (Hrsg.). Neurologische Erkrankungen in der Schwangerschaft. <u>Springer, 2007, Wien, pp 279-98.</u>
32	Geser F, Globas C, Schöls L, Wenning G. Multiple System Atrophy. In: Brice A, Pulst S-M (eds.). Spinocerebellar Degenerations: Ataxias and Spastic Paraplegias. <u>Elsevier, 2007, Burlington, pp 78-112.</u>
33	Geser F, Scholz SW, Wenning GK. Progressive supranuclear palsy and corticobasal degeneration. In: Lajtha A (ed.). Handbook of Neurochemistry and Molecular Neurobiology, 3 <sup>rd</sup> ed. <u>Springer, 2007, Berlin, pp 127-37.</u>
34	Geser F, Wenning GK. Multiple system atrophy. In: Lajtha A (ed.) Handbook of Neurochemistry and Molecular Neurobiology, 3 <sup>rd</sup> ed. <u>Springer, 2007, Berlin.</u>
35	Wenning GK, Stefanova N. Inwieweit spiegeln Tiermodelle die menschlichen Erkrankungen Parkinson-Krankheit und Multisystematrophie wieder?. <u>Roche Pharma Symposiumband, 2007.</u>
36	Geser F & Wenning GK. Primary autonomic failure. In: Schapira AHV (ed.). Neurology and clinical neuroscience. <u>Mosby-Elsevier, 2007, Philadelphia, pp 372-95.</u>
37	Poewe W & Wenning GK. Parkinson Plus Disorders. In: Schapira AHV (ed.). Neurology and clinical neuroscience. <u>Mosby-Elsevier, 2007, Philadelphia, pp 961-82.</u>
38	Stampfer-Kountschev M, Wenning GK. Autonomic failure in dementia with Lewy bodies. In: Jiritsu-Shinkei-Gaku (des.). Autonomic Neuroscience (Japanese translation of Primer on the Autonomic Nervous System. Robertson D, Biaggioni I, Burnstock, G, and Low PA (eds.). 2 <sup>nd</sup> English edition, 2004). <u>Elsevier, 2007, Tokyo.</u>
39	Geser F, Egger K, Wenning GK. A face to remember .... In: Reich SG (ed.). Movement Disorders: 100 Instructive cases. <u>Taylor &amp; Francis Books, 2008, Abingdon, pp 135-8.</u>
40	Wenning GK, Granata R. Multisystematrophie (MSA). In: Oertel, Poewe, Deuschl. Bewegungsstörungen. <u>Thieme, 2010.</u>

41	Geser F, Jellinger K, Köllensperger M, Stefanova N, Wenning GK. Multiple system atrophy: aetiology, pathology and pathogenesis. In: Movement Disorders 4. Fahn, Lang, & Schapira (eds.). <u>Elsevier, 2010, Philadelphia, pp 321-39.</u>
42	Stefanova N, Wenning GK. Experimental models to define multiple system atrophy and autonomic failure. In: C. Mathias, R. Bannister (eds.). Autonomic Failure 5 <sup>th</sup> Edition. <u>2008</u>
43	Geser F, Egger K, Wenning GK. A face to remember. In: Movement Disorders: 100 Instructive cases. Ed: Reich SG (ed.). <u>Taylor &amp; Francis Books, Abingdon, England. 2008. pp. 135-138</u>
44	Köllensperger M, Wenning GK. Parkinson-Plus Disorders. In: Therapeutics of Parkinson's Disease and Other Movement Disorders. Hallett, Poewe (eds.). <u>John Wiley &amp; Sons, Ltd., Chichester, England. 2008</u>
45	Geser F, Jellinger K, Köllensperger M, Stefanova N, Wenning GK. Multiple system atrophy: Aetiology, pathology and pathogenesis. In: Movement Disorders 4, Blue Books in Neurology. Fahn S, Lang A, Schapira A (eds.). <u>Elsevier, Philadelphia, USA. 2010. pp. 321-339</u>
46	Stemberger S, Stampfer M, Wenning GK. Dementia with Lewy Bodies. In: Primer on the Autonomic Nervous System. David Robertson, Italo Biaggioni, Geoffery Burnstock, and Philip Low for the American Autonomic Society (eds.). <u>Elsevier. 2011. in press</u>
47	Kuzdas D, Wenning G. Combination lesion models of MSA. In: Neuromethods: Animal Models of Movement Disorders. Lane E, Dunnett S (eds.). <u>Humana Press. 2011. in press</u>
48	Stemberger S, Wenning GK. Multiple System Atrophy. In: Uncommon Causes of Movement Disorders. Gálvez-Jiménez N, Tuite P (eds.). <u>Cambridge University Press, Cambridge, England. 2011. in press</u>
49	Wenning GK, Granata R. Multisystematrophie (MSA). In: Parkinsonsyndrome und andere Bewegungsstörungen. Oertel W, Deuschl G, Poewe W (eds.). <u>Thieme Verlag, Stuttgart, Deutschland. 2011. in press</u>
50	Poewe W, Wenning G, Bürk K, Dodel R. Skalen zur Beurteilung von Schweregrad und Beeinträchtigung bei Bewegungsstörungen. In: Parkinsonsyndrome und andere Bewegungsstörungen. Oertel W, Deuschl G. Poewe W (eds.). <u>Thieme, Deutschland. 2011. in press</u>
51	Münchau A , Wenning GK, Poewe W. Atypische Parkinsonsyndrome. In: Parkinsonsyndrome und andere Bewegungsstörungen. Oertel W, Deuschl G. Poewe W (eds.). <u>Thieme, Deutschland. 2011. in press</u>
52	Wenning GK, Krismer F, Gilman S. Multiple System Atrophy (MSA). In: Handbook of the Cerebellum and Cerebellar Disorders. Manto M (ed.). <u>Springer Science + Media. 2011. in press</u>
53	Wenning GK, Krismer F. Multiple system atrophy. In: Handbook of Clinical Neurology. <u>Springer. 2011. In press</u>
54	Wenning GK, Krismer F. Multiple System Atrophy. In: Movement Disorders (Oxford Textbooks in Clinical Neurology). <u>Oxford university press, Oxford, England. 2011. In press</u>
55	Colosimo C, Riley D, Wenning GK. Handbook of Atypical Parkinsonism. <u>Cambridge University Press. Cambridge, UK, 2011</u>
56	Granata R, Wenning GK. Multiple System Atrophy. In: Handbook of Atypical Parkinsonism. Colosimo, Riley, Wenning (eds.). <u>Cambridge University Press, Cambridge</u>